新冠肺炎(又稱武漢肺炎、或COVID-19病毒感染)這幾個禮拜對台灣衝擊很大,還好疫苗已經研發出來,更已經在全世界普遍施打,很多報告都已經發表,已經到貨的疫苗,雖然數量還不大夠,但已經引起社會上廣大的討論,甚至開始流傳一些錯誤的訊息,這些訊息透過電視、網路、社群媒體到處流傳,對於防疫已經開始有負面的影響了!
這樣下去不行!
我整理了幾大洗腎患者打新冠肺炎疫苗的理由,希望導正觀念,才能早日打贏抗疫這場仗。
一、腎友更容易得到新冠肺炎!
腎友們需要到洗腎室接受治療,一周三次,一年就要156次,這途中遇到的每一個人,都是潛在的感染來源,更別說治療時間三四個小時都是共處一室,床與床之間的距離規定是0.8公尺,要保持安全社交距離,幾乎是不可能的。
數據上來說,外國的經驗告訴我們,洗腎患者的盛行率是一般人的22倍!
二、腎友得到新冠肺炎後,比一般人嚴重!
腎友若得到新冠肺炎,有一半的機會嚴重到需要住院,20%-30%的機會會死亡。
或許有人可能覺得:五分之一的機率死亡還是三分之一的機會沒甚麼,但是……一般人(整體來說)得到新冠肺炎的死亡率是只有大約2%,得到流感而重症死亡的機會不到千分之一,這樣看起來,是不是更應該趕快得到保護才對呢?
三、打了疫苗,真的有效!
英國(因為他們AZ疫苗打最多)一個 30000多人的研究顯示,打了AZ疫苗之後,可100%預防重症及住院的機率,也就是說打完疫苗後就算得到感染,也是輕症,輕症就類似感冒一樣,會自己痊癒。
把狠狠撲過來的老虎,瞬間變成小貓咪,可能會有點小抓傷,但是之後就沒事了嘛。
洗腎患者的真實疫苗數據還在進行當中,確實有些報告顯示抗體效價比較低。但說實在話,這和B型肝炎疫苗的情況類似啊,後來我們知道B型肝炎疫苗所產生的抗體比較低,就不打了嗎?沒有,我們打兩倍劑量,打好打滿。
之後新冠疫苗針對腎友的研究報告出來,如果真的抗體會比較不夠,那就追加劑量吧,接下來可能會有更新的做法再隨時調整吧。不管如何,抗體量都會比沒打的人來的高,打還是比較好啊~
四、為了保護家人。
從上面第2點知道,一般人得到重症死亡的機率只有2%,那為什麼年輕的醫護人員要趕快打疫苗呢?很重要的理由之一,就是因為我們也有家庭。
我們得病沒關係,但是我們無法忍受家人被我們傳染。
尤其如果是與父母親同住者,萬一傳給了年長的父母親,或者還小的孩子,那可是後悔也來不及了。年長的父母親更是高死亡率的那一群,所以先把自己保護好,進而能夠保護家人。
腎友也是類似的情況,不要因此而把病毒帶回家了。
五、周遭的人都打了,你更要一起打!
切記,打了疫苗,並不是得到金鐘罩鐵布衫穿了防彈背心,只是把轟過來的炮彈變成BB彈,還是有可能得到傳染,雖然是輕症,但也就有機會再傳染出去給別人。
那麼,周遭的腎友都打過疫苗了,他們如果得病,他們很可能只有輕症而已,但是有機會傳染給其他人,如果下一位腎友剛好是沒打疫苗的,得到重症甚至死亡的機會大增,發生憾事,很可惜,原本是有機會可以避免的呢……
六、有糖尿病、心臟病、免疫風濕疾病等等慢性病,原則上都可以打!
罹患有其他慢性病者,一樣是高風險族群,台灣疾管局也納入優先接種對象之一,這表示專家們都認為應該接種,所以這些慢性病並不是不能打的原因喔!
不是理由一:電視上某某名嘴說不能打某某疫苗(這不能當理由)
拜託,在電視上講講話有需要付任何責任嗎?如果因此而得病、進而產生不幸的結果,他有事嗎?
記住,六都首長不分藍白綠,都在鏡頭面前打過疫苗了,病毒可沒有在管你甚麼政治傾向喔,要判斷一個人可不可信,是從那個人的實際作為判斷,而不是聽到他說的甚麼話。
不是理由二:我要等某某疫苗,聽說那個疫苗比較好
台灣在國際間處境艱難,疫苗都要進飛機飛上天了,才能告訴國人這個好消息,我可沒把握後面還有多少疫苗會來,而來了之後,會不會輪到你我可沒把握。而且你看不管哪一支疫苗,現在只要有風聲哪裡有疫苗可打,就都搶成那樣了,要是機會輪到你,就去打吧。我、我老婆、我母親全家都已經打了AZ疫苗,看過各國的報告之後,我認為不需要挑疫苗,只要好好與醫師討論,把心中疑惑講出來,充分討論就可以了。
今天最新的英國研究,一個38萬人的分析,AZ 疫苗和 BNT 疫苗的對於施打對象的保護力幾乎一模一樣,減少有症狀的感染達到了79-80%。這大概是第一個把AZ疫苗和BNT疫苗直接對比的研究,結果一樣好。
最好的疫苗,就是輪到你馬上可以打的那一支疫苗。
不是理由三:AZ疫苗打了會不舒服、會血栓。
要先知道,任何藥物或疫苗都有極低的機會會產生不良反應,據我看到的資料顯示,AZ疫苗會產生血栓的機率,大約等於出門坐車發生意外的機率、有一說是和出門被雷打到的機會類似。這意思是:
既然你不會因為害怕車禍,而不敢坐車,那就沒有必要因為害怕血栓,而不敢打疫苗。
既然你不會因為害怕被雷打到,而不敢出門,那就沒有必要因為害怕血栓,而不敢打疫苗。
另外,打完AZ疫苗,確實一兩天內常見有頭痛、發燒、肌肉痠痛等等不適,通常吃一點症狀治療的藥物就會改善,我個人認為忍耐一兩天,就可以得到完整的保護力,是非常值得的。
P.S 身體有特殊情況,還是建議您和主治醫師討論過後,再做決定。
{2147300:2PK6SKZX};{2147300:PHHXQM7H};{2147300:KV6VV42F};{2147300:2PK6SKZX};{2147300:PHHXQM7H};{2147300:KV6VV42F};{2147300:2PK6SKZX};{2147300:PHHXQM7H};{2147300:KV6VV42F}
nature
default
asc
0
3171
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A200%2C%22request_next%22%3A50%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22LPMP7AAS%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3B%26%23x6A23%3B%26%23x54C1%3B%26%23x74B0%3B%26%23x5957%3B%26%23x88DD%3B%20MR2490%20%26%23x81EA%3B%26%23x884C%3B%26%23x914D%3B%26%23x7F6E%3B.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fwww.moebelmaster.de%5C%2FMusterring-Garnitur-MR2490-zum-selbst-konfigurieren%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fwww.moebelmaster.de%5C%2FMusterring-Garnitur-MR2490-zum-selbst-konfigurieren%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22webpage%22%2C%22title%22%3A%22%5Cu6a23%5Cu54c1%5Cu74b0%5Cu5957%5Cu88dd%20MR2490%20%5Cu81ea%5Cu884c%5Cu914d%5Cu7f6e%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.moebelmaster.de%5C%2FMusterring-Garnitur-MR2490-zum-selbst-konfigurieren%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-04-09T12%3A59%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22PHHXQM7H%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BAZD1222%20US%20Phase%20III%20primary%20analysis%20confirms%20safety%20and%20efficacy.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fwww.astrazeneca.com%5C%2Fcontent%5C%2Fastraz%5C%2Fmedia-centre%5C%2Fpress-releases%5C%2F2021%5C%2Fazd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy.html%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fwww.astrazeneca.com%5C%2Fcontent%5C%2Fastraz%5C%2Fmedia-centre%5C%2Fpress-releases%5C%2F2021%5C%2Fazd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy.html%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22webpage%22%2C%22title%22%3A%22AZD1222%20US%20Phase%20III%20primary%20analysis%20confirms%20safety%20and%20efficacy%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.astrazeneca.com%5C%2Fcontent%5C%2Fastraz%5C%2Fmedia-centre%5C%2Fpress-releases%5C%2F2021%5C%2Fazd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy.html%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-06-10T08%3A07%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22V2K4UWQE%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BImpact%20of%20vaccination%20on%20new%20SARS-CoV-2%20infections%20in%20the%20United%20Kingdom%20%7C%20Nature%20Medicine.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41591-021-01410-w%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41591-021-01410-w%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22webpage%22%2C%22title%22%3A%22Impact%20of%20vaccination%20on%20new%20SARS-CoV-2%20infections%20in%20the%20United%20Kingdom%20%7C%20Nature%20Medicine%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41591-021-01410-w%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-06-10T07%3A51%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22KV6VV42F%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BImpact%20of%20vaccination%20on%20new%20SARS-CoV-2%20infections%20in%20the%20United%20Kingdom%20%7C%20Nature%20Medicine.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41591-021-01410-w%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41591-021-01410-w%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22webpage%22%2C%22title%22%3A%22Impact%20of%20vaccination%20on%20new%20SARS-CoV-2%20infections%20in%20the%20United%20Kingdom%20%7C%20Nature%20Medicine%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41591-021-01410-w%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-06-10T06%3A51%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22WGKSTCKU%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BMedia%20Statement%20from%20CDC%20Director%20Rochelle%20P.%20Walensky%2C%20MD%2C%20MPH%2C%20On%20COVID-19%20Vaccination%20at%20Dialysis%20Centers%20%7C%20CDC%20Online%20Newsroom%20%7C%20CDC.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fwww.cdc.gov%5C%2Fmedia%5C%2Freleases%5C%2F2021%5C%2Fs0325-vaccines-dialysis-centers.html%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fwww.cdc.gov%5C%2Fmedia%5C%2Freleases%5C%2F2021%5C%2Fs0325-vaccines-dialysis-centers.html%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22webpage%22%2C%22title%22%3A%22Media%20Statement%20from%20CDC%20Director%20Rochelle%20P.%20Walensky%2C%20MD%2C%20MPH%2C%20On%20COVID-19%20Vaccination%20at%20Dialysis%20Centers%20%7C%20CDC%20Online%20Newsroom%20%7C%20CDC%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.cdc.gov%5C%2Fmedia%5C%2Freleases%5C%2F2021%5C%2Fs0325-vaccines-dialysis-centers.html%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-06-10T06%3A01%3A31Z%22%7D%7D%2C%7B%22key%22%3A%222PK6SKZX%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BAt%20least%20156%20reasons%20to%20prioritize%20COVID-19%20vaccination%20in%20patients%20receiving%20in-centre%20haemodialysis%20%7C%20Nephrology%20Dialysis%20Transplantation%20%7C%20Oxford%20Academic.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fndt%5C%2Farticle%5C%2F36%5C%2F4%5C%2F571%5C%2F6104929%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fndt%5C%2Farticle%5C%2F36%5C%2F4%5C%2F571%5C%2F6104929%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22webpage%22%2C%22title%22%3A%22At%20least%20156%20reasons%20to%20prioritize%20COVID-19%20vaccination%20in%20patients%20receiving%20in-centre%20haemodialysis%20%7C%20Nephrology%20Dialysis%20Transplantation%20%7C%20Oxford%20Academic%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fndt%5C%2Farticle%5C%2F36%5C%2F4%5C%2F571%5C%2F6104929%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-06-10T05%3A58%3A18Z%22%7D%7D%2C%7B%22key%22%3A%223XV4NQXV%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lindley%20and%20Kim%22%2C%22parsedDate%22%3A%222018-11-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BLindley%2C%20M.%20C.%20%26amp%3B%20Kim%2C%20D.%20K.%20Increasing%20Protection%20of%20Dialysis%20Patients%20against%20Influenza.%20%26lt%3Bi%26gt%3BCJASN%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B13%26lt%3B%5C%2Fb%26gt%3B%2C%201624%26%23x2013%3B1626%20%282018%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Increasing%20Protection%20of%20Dialysis%20Patients%20against%20Influenza%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Megan%20C.%22%2C%22lastName%22%3A%22Lindley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20K.%22%2C%22lastName%22%3A%22Kim%22%7D%5D%2C%22abstractNote%22%3A%22Adults%20with%20CKD%20or%20ESKD%20have%20impaired%20immune%20systems%20and%20are%20at%20high%20risk%20of%20infectious%20disease%5Cu2013related%20illness%2C%20including%20significantly%20increased%20risk%20of%20serious%20complications%20from%20influenza%20infection%20%28%5B1%5D%5B1%5D%2C%5B2%5D%5B2%5D%29.%20The%20Advisory%20Committee%20on%20Immunization%20Practices%20recommends%20routine%20influenza%22%2C%22date%22%3A%222018%5C%2F11%5C%2F07%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.2215%5C%2FCJN.11670918%22%2C%22ISSN%22%3A%221555-9041%2C%201555-905X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fcjasn.asnjournals.org%5C%2Fcontent%5C%2F13%5C%2F11%5C%2F1624%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222018-11-08T02%3A37%3A03Z%22%7D%7D%2C%7B%22key%22%3A%222UR8EI9V%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Miskulin%20et%20al.%22%2C%22parsedDate%22%3A%222018-11-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BMiskulin%2C%20D.%20C.%20%26lt%3Bi%26gt%3Bet%20al.%26lt%3B%5C%2Fi%26gt%3B%20High-Dose%20Seasonal%20Influenza%20Vaccine%20in%20Patients%20Undergoing%20Dialysis.%20%26lt%3Bi%26gt%3BCJASN%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B13%26lt%3B%5C%2Fb%26gt%3B%2C%201703%26%23x2013%3B1711%20%282018%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22High-Dose%20Seasonal%20Influenza%20Vaccine%20in%20Patients%20Undergoing%20Dialysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dana%20C.%22%2C%22lastName%22%3A%22Miskulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%20E.%22%2C%22lastName%22%3A%22Weiner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hocine%22%2C%22lastName%22%3A%22Tighiouart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%20K.%22%2C%22lastName%22%3A%22Lacson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Klemens%20B.%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Taimur%22%2C%22lastName%22%3A%22Dad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harold%20J.%22%2C%22lastName%22%3A%22Manley%22%7D%5D%2C%22abstractNote%22%3A%22Visual%20Abstract%5Cn%26lt%3Bimg%20class%3D%26quot%3Bhighwire-fragment%20fragment-image%26quot%3B%20alt%3D%26quot%3BFigure1%26quot%3B%20src%3D%26quot%3Bhttps%3A%5C%2F%5C%2Fcjasn.asnjournals.org%5C%2Fcontent%5C%2Fclinjasn%5C%2F13%5C%2F11%5C%2F1703%5C%2FF1.medium.gif%26quot%3B%20width%3D%26quot%3B440%26quot%3B%20height%3D%26quot%3B248%26quot%3B%5C%2F%26gt%3BDownload%20figureOpen%20in%20new%20tabDownload%20powerpoint%5Cn%5CnBackground%20and%20objectives%20High-dose%20influenza%20vaccine%2C%20which%20contains%20fourfold%20more%20antigen%20than%20standard%20dose%2C%20is%20associated%20with%20fewer%20cases%20of%20influenza%20and%20less%20influenza-related%20morbidity%20in%20the%20elderly%20general%20population.%20Whether%20the%20high-dose%20influenza%20vaccine%20benefits%20patients%20on%20dialysis%2C%20whose%20immune%20response%20to%20vaccination%20is%20less%20robust%20than%20that%20of%20healthy%20patients%2C%20is%20uncertain.%5CnDesign%2C%20setting%2C%20participants%2C%20%26amp%3B%20measurements%20We%20compared%20hospitalizations%20and%20deaths%20during%20the%202015%5Cu20132016%20and%202016%5Cu20132017%20influenza%20seasons%20by%20vaccine%20type%20%28standard%20trivalent%2C%20standard%20quadrivalent%2C%20and%20high-dose%20trivalent%20influenza%20vaccine%29%20administered%20within%20a%20national%20dialysis%20organization.%20The%20association%20of%20vaccine%20type%20with%20outcomes%20was%20estimated%20using%20Cox%20proportional%20hazards%20regression%20with%20adjustment%20for%20patient%20factors%20and%20%5Cu201ccenter%20effect.%5Cu201d%20Analyses%20were%20stratified%20by%20age%20and%20dialysis%20modality.%5CnResults%20Between%20September%201%20and%20December%2031%2C%202015%2C%20standard%20dose%20trivalent%2C%20standard%20dose%20quadrivalent%2C%20and%20high-dose%20trivalent%20influenza%20vaccines%20were%20administered%20to%203057%20%2831%25%29%2C%205981%20%2861%25%29%2C%20and%20805%20%288%25%29%20patients%2C%20respectively.%20The%20adjusted%20rates%20of%20first%20hospitalizations%20by%20vaccine%20type%20during%20the%20influenza%20season%20were%208.43%2C%207.88%2C%20and%207.99%20per%20100%20patient-months%2C%20respectively%2C%20and%20the%20adjusted%20rates%20of%20death%20were%201.00%2C%200.97%2C%20and%201.04%2C%20respectively.%20These%20differences%20were%20not%20significant.%20In%202016%2C%203614%20%2839%25%29%20received%20quadrivalent%20vaccine%2C%20and%205700%20%2861%25%29%20received%20high-dose%20trivalent%20vaccine.%20The%20adjusted%20rates%20of%20first%20hospitalization%20by%20vaccine%20type%20were%208.71%20and%208.04%20per%20100%20patient-months%2C%20respectively%2C%20and%20the%20adjusted%20rates%20of%20death%20were%200.98%20and%201.02%2C%20respectively.%20Receipt%20of%20high%20dose%20was%20associated%20with%20a%20significant%20reduction%20in%20hospitalization%20%28hazard%20ratio%2C%200.93%3B%2095%25%20confidence%20interval%2C%200.86%20to%201.00%3B%20P%3D0.04%29%3B%20there%20was%20no%20significant%20association%20with%20death.%20There%20was%20no%20significant%20heterogeneity%20of%20either%20association%20by%20age%20group%20or%20dialysis%20modality.%5CnConclusions%20Receipt%20of%20high-dose%20compared%20with%20standard%20dose%20influenza%20vaccine%20in%202016%5Cu20132017%20was%20associated%20with%20lower%20rates%20of%20hospitalization%20in%20patients%20on%20dialysis%2C%20although%20that%20was%20not%20seen%20in%202015%5Cu20132016.%22%2C%22date%22%3A%222018%5C%2F11%5C%2F07%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.2215%5C%2FCJN.03390318%22%2C%22ISSN%22%3A%221555-9041%2C%201555-905X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fcjasn.asnjournals.org%5C%2Fcontent%5C%2F13%5C%2F11%5C%2F1703%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222018-11-08T02%3A36%3A55Z%22%7D%7D%2C%7B%22key%22%3A%22M2F2WJGG%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BSign%20In.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fcjasn.asnjournals.org%5C%2Fcontent%5C%2F13%5C%2F3%5C%2F361.full%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fcjasn.asnjournals.org%5C%2Fcontent%5C%2F13%5C%2F3%5C%2F361.full%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22webpage%22%2C%22title%22%3A%22Sign%20In%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fcjasn.asnjournals.org%5C%2Fcontent%5C%2F13%5C%2F3%5C%2F361.full%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222018-06-23T02%3A14%3A58Z%22%7D%7D%2C%7B%22key%22%3A%2244UJW6KG%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kalim%20et%20al.%22%2C%22parsedDate%22%3A%222018-02-14%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BKalim%2C%20S.%20%26lt%3Bi%26gt%3Bet%20al.%26lt%3B%5C%2Fi%26gt%3B%20Extended%20Duration%20Nocturnal%20Hemodialysis%20and%20Changes%20in%20Plasma%20Metabolite%20Profiles.%20%26lt%3Bi%26gt%3BCJASN%26lt%3B%5C%2Fi%26gt%3B%20CJN.08790817%20%282018%29%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.2215%5C%2FCJN.08790817%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.2215%5C%2FCJN.08790817%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Extended%20Duration%20Nocturnal%20Hemodialysis%20and%20Changes%20in%20Plasma%20Metabolite%20Profiles%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sahir%22%2C%22lastName%22%3A%22Kalim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ron%22%2C%22lastName%22%3A%22Wald%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20T.%22%2C%22lastName%22%3A%22Yan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20B.%22%2C%22lastName%22%3A%22Goldstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mercedeh%22%2C%22lastName%22%3A%22Kiaii%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dihua%22%2C%22lastName%22%3A%22Xu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anders%20H.%22%2C%22lastName%22%3A%22Berg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clary%22%2C%22lastName%22%3A%22Clish%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ravi%22%2C%22lastName%22%3A%22Thadhani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eugene%20P.%22%2C%22lastName%22%3A%22Rhee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%22%2C%22lastName%22%3A%22Perl%22%7D%5D%2C%22abstractNote%22%3A%22Background%20and%20objectives%20In-center%2C%20extended%20duration%20nocturnal%20hemodialysis%20has%20been%20associated%20with%20variable%20clinical%20benefits%2C%20but%20the%20effect%20of%20extended%20duration%20hemodialysis%20on%20many%20established%20uremic%20solutes%20and%20other%20components%20of%20the%20metabolome%20is%20unknown.%20We%20determined%20the%20magnitude%20of%20change%20in%20metabolite%20profiles%20for%20patients%20on%20extended%20duration%20nocturnal%20hemodialysis.%5CnDesign%2C%20setting%2C%20participants%2C%20%26amp%3B%20measurements%20In%20a%2052-week%20prospective%2C%20observational%20study%2C%20we%20followed%2033%20patients%20receiving%20conventional%20thrice%20weekly%20hemodialysis%20who%20converted%20to%20nocturnal%20hemodialysis%20%287%5Cu20138%20hours%20per%20session%2C%20three%20times%20per%20week%29.%20A%20separate%20group%20of%2020%20patients%20who%20remained%20on%20conventional%20hemodialysis%20%283%5Cu20134%20hours%20per%20session%2C%20three%20times%20per%20week%29%20served%20as%20a%20control%20group.%20For%20both%20groups%2C%20we%20applied%20liquid%20chromatography-mass%20spectrometry%5Cu2013based%20metabolite%20profiling%20on%20stored%20plasma%20samples%20collected%20from%20all%20participants%20at%20baseline%20and%20after%201%20year.%20We%20examined%20longitudinal%20changes%20in%20164%20metabolites%20among%20those%20who%20remained%20on%20conventional%20hemodialysis%20and%20those%20who%20converted%20to%20nocturnal%20hemodialysis%20using%20Wilcoxon%20rank%20sum%20tests%20adjusted%20for%20multiple%20comparisons%20%28false%20discovery%20rate%20%26lt%3B0.05%29.%5CnResults%20On%20average%2C%20the%20nocturnal%20group%20had%209.6%20hours%20more%20dialysis%20per%20week%20than%20the%20conventional%20group.%20Among%20164%20metabolites%2C%20none%20changed%20significantly%20from%20baseline%20to%20study%20end%20in%20the%20conventional%20group.%20Twenty-nine%20metabolites%20changed%20in%20the%20nocturnal%20group%2C%2021%20of%20which%20increased%20from%20baseline%20to%20study%20end%20%28including%20all%20branched-chain%20amino%20acids%29.%20Eight%20metabolites%20decreased%20after%20conversion%20to%20nocturnal%20dialysis%2C%20including%20l-carnitine%20and%20acetylcarnitine.%20By%20contrast%2C%20several%20established%20uremic%20retention%20solutes%2C%20including%20p-cresol%20sulfate%2C%20indoxyl%20sulfate%2C%20and%20trimethylamine%20N-oxide%2C%20did%20not%20change%20with%20extended%20dialysis.%5CnConclusions%20Across%20a%20wide%20array%20of%20metabolites%20examined%2C%20extended%20duration%20hemodialysis%20was%20associated%20with%20modest%20changes%20in%20the%20plasma%20metabolome%2C%20with%20most%20differences%20relating%20to%20metabolite%20increases%2C%20despite%20increased%20dialysis%20time.%20Few%20metabolites%20showed%20reduction%20with%20more%20dialysis%2C%20and%20no%20change%20in%20several%20established%20uremic%20toxins%20was%20observed.%22%2C%22date%22%3A%222018-02-14%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.2215%5C%2FCJN.08790817%22%2C%22ISSN%22%3A%221555-9041%2C%201555-905X%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fcjasn.asnjournals.org%5C%2Fcontent%5C%2Fearly%5C%2F2018%5C%2F02%5C%2F13%5C%2FCJN.08790817%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222018-06-19T08%3A18%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22I6YNFXJU%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3Bkck_t25.gif%20%28782%26%23xD7%3B328%29.%20%26lt%3Bi%26gt%3BKDOQI%20GFR%20%26gt%3B20%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fwww2.kidney.org%5C%2Fprofessionals%5C%2Fkdoqi%5C%2Fguidelines_ckd%5C%2FGif_File%5C%2Fkck_t25.gif%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fwww2.kidney.org%5C%2Fprofessionals%5C%2Fkdoqi%5C%2Fguidelines_ckd%5C%2FGif_File%5C%2Fkck_t25.gif%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22webpage%22%2C%22title%22%3A%22kck_t25.gif%20%28782%5Cu00d7328%29%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww2.kidney.org%5C%2Fprofessionals%5C%2Fkdoqi%5C%2Fguidelines_ckd%5C%2FGif_File%5C%2Fkck_t25.gif%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222018-03-22T07%3A46%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22YVMW6YWF%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3Bkck_t24.gif%20%28535%26%23xD7%3B548%29.%20%26lt%3Bi%26gt%3BKDOQI%20GFR%20%26lt%3B21%20Y%5C%2FO%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fwww2.kidney.org%5C%2Fprofessionals%5C%2Fkdoqi%5C%2Fguidelines_ckd%5C%2FGif_File%5C%2Fkck_t24.gif%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fwww2.kidney.org%5C%2Fprofessionals%5C%2Fkdoqi%5C%2Fguidelines_ckd%5C%2FGif_File%5C%2Fkck_t24.gif%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22webpage%22%2C%22title%22%3A%22kck_t24.gif%20%28535%5Cu00d7548%29%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww2.kidney.org%5C%2Fprofessionals%5C%2Fkdoqi%5C%2Fguidelines_ckd%5C%2FGif_File%5C%2Fkck_t24.gif%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222018-03-22T07%3A45%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22PY6UXGKJ%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Schwartz%20and%20Work%22%2C%22parsedDate%22%3A%222009-11-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BSchwartz%2C%20G.%20J.%20%26amp%3B%20Work%2C%20D.%20F.%20Measurement%20and%20Estimation%20of%20GFR%20in%20Children%20and%20Adolescents.%20%26lt%3Bi%26gt%3BCJASN%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B4%26lt%3B%5C%2Fb%26gt%3B%2C%201832%26%23x2013%3B1843%20%282009%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Measurement%20and%20Estimation%20of%20GFR%20in%20Children%20and%20Adolescents%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%20J.%22%2C%22lastName%22%3A%22Schwartz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dana%20F.%22%2C%22lastName%22%3A%22Work%22%7D%5D%2C%22abstractNote%22%3A%22GFR%20is%20the%20best%20indicator%20of%20renal%20function%20in%20children%20and%20adolescents%20and%20is%20critical%20for%20diagnosing%20acute%20and%20chronic%20kidney%20impairment%2C%20intervening%20early%20to%20prevent%20end-stage%20renal%20failure%2C%20prescribing%20nephrotoxic%20drugs%20and%20drugs%20cleared%20by%20a%20failing%20kidney%2C%20and%20monitoring%20for%20side%20effects%20of%20medications.%20Renal%20inulin%20clearance%20was%20the%20gold%20standard%20for%20GFR%20but%20is%20compromised%20by%20lack%20of%20availability%2C%20difficult%20assays%2C%20and%20problems%20of%20collecting%20timed%20urine%20samples%2C%20especially%20in%20children%20with%20vesicoureteral%20reflux%20or%20bladder%20dysfunction.%20Creatinine%20clearance-based%20estimates%20of%20GFR%20are%20often%20used%20in%20pediatrics.%20The%20addition%20of%20cimetidine%20to%20eliminate%20creatinine%20secretion%20permits%20accurate%20measurement%20of%20GFR%20in%20those%20who%20can%20completely%20empty%20their%20bladders%20to%20provide%20timed%20urine%20collections.%20Radioisotopes%20are%20used%20in%20plasma%20disappearance%20GFR%20determinations%3B%20however%2C%20these%20are%20not%20ideal%20for%20use%20in%20children%2C%20especially%20for%20repeated%20studies.%20The%20plasma%20disappearance%20of%20iohexol%20serves%20as%20a%20promising%20alternative%20GFR%20marker%2C%20because%20it%20is%20safe%20and%20not%20radioactive%2C%20easily%20measured%2C%20not%20metabolized%20or%20transported%20by%20the%20kidney%2C%20and%20excreted%20primarily%20by%20glomerular%20filtration.%20GFR%20estimating%20equations%2C%20based%20on%20serum%20concentrations%20of%20creatinine%20or%20cystatin%20C%2C%20are%20popular%20clinically%20and%20in%20research%20studies.%20Efforts%20are%20ongoing%20to%20improve%20these%20estimating%20equations%20for%20children%20and%20make%20the%20results%20readily%20available%20to%20clinicians%20obtaining%20standard%20chemistry%20profiles%2C%20as%20is%20being%20done%20for%20adults.%20However%2C%20at%20this%20time%2C%20there%20is%20no%20dependable%20substitute%20for%20an%20accurately%20determined%20GFR%2C%20and%20iohexol%20plasma%20disappearance%20offers%20the%20best%20combination%20of%20safety%2C%20accuracy%2C%20and%20reproducible%20precision.%22%2C%22date%22%3A%2211%5C%2F01%5C%2F2009%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.2215%5C%2FCJN.01640309%22%2C%22ISSN%22%3A%221555-9041%2C%201555-905X%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fcjasn.asnjournals.org%5C%2Fcontent%5C%2F4%5C%2F11%5C%2F1832%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222018-03-22T07%3A20%3A30Z%22%7D%7D%2C%7B%22key%22%3A%226B42L6VU%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Patel%20et%20al.%22%2C%22parsedDate%22%3A%222008-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPatel%2C%20N.%2C%20Dalal%2C%20P.%20%26amp%3B%20Panesar%2C%20M.%20Dialysis%20disequilibrium%20syndrome%3A%20a%20narrative%20review.%20%26lt%3Bi%26gt%3BSemin%20Dial%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B21%26lt%3B%5C%2Fb%26gt%3B%2C%20493%26%23x2013%3B498%20%282008%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Dialysis%20disequilibrium%20syndrome%3A%20a%20narrative%20review%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nilang%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pranav%22%2C%22lastName%22%3A%22Dalal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mandip%22%2C%22lastName%22%3A%22Panesar%22%7D%5D%2C%22abstractNote%22%3A%22Dialysis%20Disequilibrium%20Syndrome%20%28DDS%29%20is%20characterized%20by%20neurological%20symptoms%20caused%20by%20rapid%20removal%20of%20urea%20during%20hemodialysis.%20It%20develops%20primarily%20from%20an%20osmotic%20gradient%20that%20develops%20between%20the%20brain%20and%20the%20plasma%20as%20a%20result%20of%20rapid%20hemodialysis.%20This%20results%20in%20brain%20edema%20that%20manifests%20as%20neurological%20symptoms%20such%20as%20headache%2C%20nausea%2C%20vomiting%2C%20muscle%20cramps%2C%20tremors%2C%20disturbed%20consciousness%2C%20and%20convulsions.%20In%20severe%20cases%2C%20patients%20can%20die%20from%20advanced%20cerebral%20edema.%20Recent%20advancements%20in%20cell%20biology%20implicate%20the%20role%20of%20urea%20disequilibrium%20%28with%20a%20smaller%20contribution%20from%20organic%20osmolytes%29%20as%20the%20pathophysiological%20mechanism%20responsible%20for%20this%20syndrome.%20In%20this%20review%2C%20we%20discuss%20the%20pathogenesis%2C%20clinical%20features%20and%20prevention%20of%20DDS.%22%2C%22date%22%3A%222008%20Sep-Oct%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fj.1525-139X.2008.00474.x%22%2C%22ISSN%22%3A%221525-139X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222018-02-16T08%3A13%3A52Z%22%7D%7D%2C%7B%22key%22%3A%22BB5AMDZR%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zepeda-Orozco%20and%20Quigley%22%2C%22parsedDate%22%3A%222012-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BZepeda-Orozco%2C%20D.%20%26amp%3B%20Quigley%2C%20R.%20Dialysis%20disequilibrium%20syndrome.%20%26lt%3Bi%26gt%3BPediatr%20Nephrol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B27%26lt%3B%5C%2Fb%26gt%3B%2C%202205%26%23x2013%3B2211%20%282012%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Dialysis%20disequilibrium%20syndrome%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Zepeda-Orozco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raymond%22%2C%22lastName%22%3A%22Quigley%22%7D%5D%2C%22abstractNote%22%3A%22The%20dialysis%20disequilibrium%20syndrome%20is%20a%20rare%20but%20serious%20complication%20of%20hemodialysis.%20Despite%20the%20fact%20that%20maintenance%20hemodialysis%20has%20been%20a%20routine%20procedure%20for%20over%2050%5Cu00a0years%2C%20this%20syndrome%20remains%20poorly%20understood.%20The%20signs%20and%20symptoms%20vary%20widely%20from%20restlessness%20and%20headache%20to%20coma%20and%20death.%20While%20cerebral%20edema%20and%20increased%20intracranial%20pressure%20are%20the%20primary%20contributing%20factors%20to%20this%20syndrome%20and%20are%20the%20target%20of%20therapy%2C%20the%20precise%20mechanisms%20for%20their%20development%20remain%20elusive.%20Treatment%20of%20this%20syndrome%20once%20it%20has%20developed%20is%20rarely%20successful.%20Thus%2C%20measures%20to%20avoid%20its%20development%20are%20crucial.%20In%20this%20review%2C%20we%20will%20examine%20the%20pathophysiology%20of%20this%20syndrome%20and%20discuss%20the%20factors%20to%20consider%20in%20avoiding%20its%20development.%22%2C%22date%22%3A%222012-12%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00467-012-2199-4%22%2C%22ISSN%22%3A%220931-041X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC3491204%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222018-02-16T08%3A13%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22TGJP9MGR%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BSign%20In.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fcjasn.asnjournals.org%5C%2Fcontent%5C%2Fearly%5C%2F2018%5C%2F02%5C%2F01%5C%2FCJN.11131017.full%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fcjasn.asnjournals.org%5C%2Fcontent%5C%2Fearly%5C%2F2018%5C%2F02%5C%2F01%5C%2FCJN.11131017.full%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22webpage%22%2C%22title%22%3A%22Sign%20In%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fcjasn.asnjournals.org%5C%2Fcontent%5C%2Fearly%5C%2F2018%5C%2F02%5C%2F01%5C%2FCJN.11131017.full%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222018-02-03T08%3A21%3A15Z%22%7D%7D%2C%7B%22key%22%3A%22H8ZLV9QF%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BSign%20In.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fcjasn.asnjournals.org%5C%2Fcontent%5C%2Fearly%5C%2F2018%5C%2F02%5C%2F01%5C%2FCJN.11131017%3Fpapetoc%3D%26amp%3Bcited-by%3Dyes%26amp%3Blegid%3Dclinjasn%3BCJN.11131017v1%23cited-by%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fcjasn.asnjournals.org%5C%2Fcontent%5C%2Fearly%5C%2F2018%5C%2F02%5C%2F01%5C%2FCJN.11131017%3Fpapetoc%3D%26amp%3Bcited-by%3Dyes%26amp%3Blegid%3Dclinjasn%3BCJN.11131017v1%23cited-by%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22webpage%22%2C%22title%22%3A%22Sign%20In%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fcjasn.asnjournals.org%5C%2Fcontent%5C%2Fearly%5C%2F2018%5C%2F02%5C%2F01%5C%2FCJN.11131017%3Fpapetoc%3D%26cited-by%3Dyes%26legid%3Dclinjasn%3BCJN.11131017v1%23cited-by%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222018-02-03T08%3A20%3A08Z%22%7D%7D%2C%7B%22key%22%3A%22WKW8ZK26%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Christopher%20W.%20McIntyre%22%2C%22parsedDate%22%3A%222018-02-02%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BChristopher%20W.%20McIntyre%2C%20F.%20R.%20S.%20Diagnosis%20and%20Treatment%20of%20Intradialytic%20Hypotension%20in%20Maintenance%20Hemodialysis%20Patients.%20%26lt%3Bi%26gt%3BCJASN%26lt%3B%5C%2Fi%26gt%3B%20%282018%29%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.2215%5C%2FCJN.11131017%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.2215%5C%2FCJN.11131017%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Diagnosis%20and%20Treatment%20of%20Intradialytic%20Hypotension%20in%20Maintenance%20Hemodialysis%20Patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabio%20R.%20Salerno%22%2C%22lastName%22%3A%22Christopher%20W.%20McIntyre%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22published%20ahead%20of%20print%20February%202%2C%202018%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.2215%5C%2FCJN.11131017%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222018-02-03T08%3A09%3A33Z%22%7D%7D%2C%7B%22key%22%3A%22XHWYNB68%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Turner%20and%20Peixoto%22%2C%22parsedDate%22%3A%222017-10-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BTurner%2C%20J.%20M.%20%26amp%3B%20Peixoto%2C%20A.%20J.%20Blood%20pressure%20targets%20for%20hemodialysis%20patients.%20%26lt%3Bi%26gt%3BKidney%20International%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B92%26lt%3B%5C%2Fb%26gt%3B%2C%20816%26%23x2013%3B823%20%282017%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Blood%20pressure%20targets%20for%20hemodialysis%20patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%20M.%22%2C%22lastName%22%3A%22Turner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aldo%20J.%22%2C%22lastName%22%3A%22Peixoto%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222017-10-01%22%2C%22language%22%3A%22English%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.kint.2017.01.038%22%2C%22ISSN%22%3A%220085-2538%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.kidney-international.org%5C%2Farticle%5C%2FS0085-2538%2817%2930418-0%5C%2Fabstract%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-10-14T00%3A42%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22UIRDGRTR%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BManual%20on%20Contrast%20Media%20v10.3%20-%20American%20College%20of%20Radiology.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fwww.acr.org%5C%2FQuality-Safety%5C%2FResources%5C%2FContrast-Manual%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fwww.acr.org%5C%2FQuality-Safety%5C%2FResources%5C%2FContrast-Manual%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22webpage%22%2C%22title%22%3A%22Manual%20on%20Contrast%20Media%20v10.3%20-%20American%20College%20of%20Radiology%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.acr.org%5C%2FQuality-Safety%5C%2FResources%5C%2FContrast-Manual%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-08-29T03%3A28%3A33Z%22%7D%7D%2C%7B%22key%22%3A%22HDJAC9B2%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22parsedDate%22%3A%222010-04-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BMRI%20with%20Gadolinium%20Policy.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fradiology.ucsf.edu%5C%2Fpatient-care%5C%2Fpatient-safety%5C%2Fcontrast%5C%2Fmri-with-contrast-gadolinium-policy%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fradiology.ucsf.edu%5C%2Fpatient-care%5C%2Fpatient-safety%5C%2Fcontrast%5C%2Fmri-with-contrast-gadolinium-policy%26lt%3B%5C%2Fa%26gt%3B%20%282010%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22webpage%22%2C%22title%22%3A%22MRI%20with%20Gadolinium%20Policy%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22Guidelines%20on%20the%20Administration%20of%20Intravenous%20Gadolinium-Containing%20Contrast%20Media%20These%20guidelines%20are%20formulated%20by%20the%20UCSF%20MRI%20Safety%20Committee%20based%20on%20FDA%20recommendations%2C%20ACR%20guidelines%20and%20published%20medical%20literature.%20Administering%20Gadolinium%20Choice%20of%20Gadolinium%20Agent%20The%20ACR%20recognizes%20three%20categories%20of%20gadolinium-containing%20contrast%20media%20with%20respect%20to%20risk%20of%20nephrogenic%20systemic%20fibrosis1.%20These%20are%20listed%20below.%20For%20simplicity%2C%20only%20those%20agents%20approved%20for%20use%20in%20the%20United%20States%20by%20the%20FDA%20are%20included%3A%22%2C%22date%22%3A%222010-04-07T14%3A43%3A51-07%3A00%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fradiology.ucsf.edu%5C%2Fpatient-care%5C%2Fpatient-safety%5C%2Fcontrast%5C%2Fmri-with-contrast-gadolinium-policy%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-08-29T03%3A26%3A10Z%22%7D%7D%2C%7B%22key%22%3A%22AQR2XTMK%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Younathan%20et%20al.%22%2C%22parsedDate%22%3A%221994-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BYounathan%2C%20C.%20M.%2C%20Kaude%2C%20J.%20V.%2C%20Cook%2C%20M.%20D.%2C%20Shaw%2C%20G.%20S.%20%26amp%3B%20Peterson%2C%20J.%20C.%20Dialysis%20is%20not%20indicated%20immediately%20after%20administration%20of%20nonionic%20contrast%20agents%20in%20patients%20with%20end-stage%20renal%20disease%20treated%20by%20maintenance%20dialysis.%20%26lt%3Bi%26gt%3BAJR%20Am%20J%20Roentgenol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B163%26lt%3B%5C%2Fb%26gt%3B%2C%20969%26%23x2013%3B971%20%281994%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Dialysis%20is%20not%20indicated%20immediately%20after%20administration%20of%20nonionic%20contrast%20agents%20in%20patients%20with%20end-stage%20renal%20disease%20treated%20by%20maintenance%20dialysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20M.%22%2C%22lastName%22%3A%22Younathan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20V.%22%2C%22lastName%22%3A%22Kaude%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20D.%22%2C%22lastName%22%3A%22Cook%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20S.%22%2C%22lastName%22%3A%22Shaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20C.%22%2C%22lastName%22%3A%22Peterson%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20This%20study%20was%20undertaken%20to%20determine%20the%20necessity%20of%20immediate%20dialysis%20after%20intravascular%20injection%20of%20contrast%20material%20in%20patients%20with%20end-stage%20renal%20disease%20who%20are%20being%20maintained%20on%20hemodialysis.%20Although%20many%20physicians%20support%20this%20practice%2C%20we%20could%20find%20no%20reports%20of%20studies%20to%20confirm%20or%20refute%20its%20necessity.%5CnSUBJECTS%20AND%20METHODS%3A%20We%20studied%2010%20patients%20being%20treated%20with%20hemodialysis%20who%20were%20undergoing%2011%20diagnostic%20procedures%20that%20required%20intravascular%20contrast%20material.%20The%20patients%20received%2040-225%20ml%20of%20nonionic%20contrast%20material%20and%20were%20followed%20up%20with%20clinical%20examination%20and%20laboratory%20analysis%20to%20determine%20any%20adverse%20effects%20from%20contrast%20administration%20or%20the%20need%20for%20dialysis%20or%20both.%5CnRESULTS%3A%20No%20significant%20changes%20in%20blood%20pressure%2C%20ECG%2C%20total%20serum%20protein%20level%20of%20osmolality%2C%20extracellular%20fluid%20volume%2C%20or%20body%20weight%20occurred%20after%20injection%20of%20contrast%20material.%20None%20of%20the%20patients%20had%20clinical%20features%20that%20necessitated%20emergent%20dialysis.%5CnCONCLUSION%3A%20We%20conclude%20that%20nonionic%20contrast%20material%20can%20be%20given%20safely%20to%20patients%20with%20end-stage%20renal%20disease%20who%20are%20being%20maintained%20on%20hemodialysis.%20Immediate%20postprocedural%20dialysis%20is%20unwarranted%20as%20a%20routine%20practice.%22%2C%22date%22%3A%22Oct%201994%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.2214%5C%2Fajr.163.4.8092045%22%2C%22ISSN%22%3A%220361-803X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-07-31T03%3A14%3A18Z%22%7D%7D%2C%7B%22key%22%3A%22DZ6FQNTS%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Niscola%20et%20al.%22%2C%22parsedDate%22%3A%222010-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BNiscola%2C%20P.%20%26lt%3Bi%26gt%3Bet%20al.%26lt%3B%5C%2Fi%26gt%3B%20The%20use%20of%20major%20analgesics%20in%20patients%20with%20renal%20dysfunction.%20%26lt%3Bi%26gt%3BCurr%20Drug%20Targets%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B11%26lt%3B%5C%2Fb%26gt%3B%2C%20752%26%23x2013%3B758%20%282010%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20use%20of%20major%20analgesics%20in%20patients%20with%20renal%20dysfunction%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pasquale%22%2C%22lastName%22%3A%22Niscola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Scaramucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gisella%22%2C%22lastName%22%3A%22Vischini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Giovannini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michele%22%2C%22lastName%22%3A%22Ferrannini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pasquale%22%2C%22lastName%22%3A%22Massa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paola%22%2C%22lastName%22%3A%22Tatangelo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Massimo%22%2C%22lastName%22%3A%22Galletti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roberto%22%2C%22lastName%22%3A%22Palumbo%22%7D%5D%2C%22abstractNote%22%3A%22Pain%20in%20patients%20with%20impaired%20renal%20function%20may%20be%20a%20significant%20problem%20requiring%20treatment%20with%20opioids.%20However%2C%20pharmacokinetic%20and%20metabolic%20changes%20associated%20with%20an%20impaired%20renal%20function%20may%20raise%20some%20concerns%20about%20side%20effects%20and%20overdosing%20associated%20with%20opioid%20agents%20in%20this%20patient%26%23039%3Bs%20population.%20In%20order%20to%20give%20recommendations%20on%20this%20issue%2C%20we%20review%20the%20available%20evidences%20on%20the%20pharmacokinetics%20and%20side%20effects%20of%20most%20common%20opioids%20used%20to%20treat%20pain.%20The%20results%20of%20this%20review%20show%20that%20the%20half-life%20of%20the%20parent%20opioid%20compounds%20and%20of%20their%20metabolites%20is%20increased%20in%20the%20presence%20of%20renal%20dysfunction%2C%20for%20which%20careful%20monitoring%20of%20the%20patient%2C%20dose%20reduction%20and%20a%20longer%20time%20interval%20between%20doses%20are%20recommended.%20Among%20opioids%2C%20morphine%20and%20codeine%20used%20with%20very%20caution%20and%20possibly%20avoided%20in%20renal%20failure%5C%2Fdialysis%20patients%3B%20tramadol%2C%20hydromorphone%20and%20oxycodone%20can%20be%20used%20with%20caution%20and%20close%20patient%26%23039%3Bs%20monitoring%2C%20whereas%20transdermal%20buprenorphine%2C%20methadone%20and%20fentanyl%5C%2Fsufentanil%20appear%20to%20be%20safe%20to%20use%20in%20patients%20with%20renal%20failure.%22%2C%22date%22%3A%22Jun%202010%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%221873-5592%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-04-25T02%3A51%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22K5IMSJVZ%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tawfic%20and%20Bellingham%22%2C%22parsedDate%22%3A%222015%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BTawfic%2C%20Q.%20A.%20%26amp%3B%20Bellingham%2C%20G.%20Postoperative%20pain%20management%20in%20patients%20with%20chronic%20kidney%20disease.%20%26lt%3Bi%26gt%3BJ%20Anaesthesiol%20Clin%20Pharmacol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B31%26lt%3B%5C%2Fb%26gt%3B%2C%206%26%23x2013%3B13%20%282015%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Postoperative%20pain%20management%20in%20patients%20with%20chronic%20kidney%20disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qutaiba%20A.%22%2C%22lastName%22%3A%22Tawfic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geoff%22%2C%22lastName%22%3A%22Bellingham%22%7D%5D%2C%22abstractNote%22%3A%22Chronic%20kidney%20disease%20%28CKD%29%20is%20a%20health%20care%20problem%20with%20increasing%20prevalence%20worldwide.%20Pain%20management%20represents%20one%20of%20the%20challenges%20in%20providing%20perioperative%20care%20for%20this%20group%20of%20patients.%20Physicians%20from%20different%20specialties%20may%20be%20involved%20in%20pain%20management%20of%20CKD%20patients%2C%20especially%20in%20advanced%20stages.%20It%20is%20important%20to%20understand%20the%20clinical%20staging%20of%20kidney%20function%20in%20CKD%20patients%20as%20the%20pharmacotherapeutic%20pain%20management%20strategies%20change%20as%20kidney%20function%20becomes%20progressively%20impaired.%20Special%20emphasis%20should%20be%20placed%20on%20dose%20adjustment%20of%20certain%20analgesics%20as%20well%20as%20prevention%20of%20further%20deterioration%20of%20renal%20function%20that%20could%20be%20induced%20by%20certain%20classes%20of%20analgesics.%20Chronic%20pain%20is%20a%20common%20finding%20in%20CKD%20patients%20which%20may%20be%20caused%20by%20the%20primary%20disease%20that%20led%20to%20kidney%20damage%20or%20can%20be%20a%20direct%20result%20of%20CKD%20and%20hemodialysis.%20The%20presence%20of%20chronic%20pain%20in%20some%20of%20the%20CKD%20patients%20makes%20postoperative%20pain%20management%20in%20these%20patients%20more%20challenging.%20This%20review%20focuses%20on%20the%20plans%20and%20challenges%20of%20postoperative%20pain%20management%20for%20patient%20at%20different%20stages%20of%20CKD%20undergoing%20surgical%20intervention%20to%20provide%20optimum%20pain%20control%20for%20this%20patient%20population.%20Further%20clinical%20studies%20are%20required%20to%20address%20the%20optimal%20medication%20regimen%20for%20postoperative%20pain%20management%20in%20the%20different%20stages%20of%20CKD.%22%2C%22date%22%3A%222015%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.4103%5C%2F0970-9185.150518%22%2C%22ISSN%22%3A%220970-9185%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC4353156%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-04-25T02%3A49%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22SFAI4NTX%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hoshino%20et%20al.%22%2C%22parsedDate%22%3A%222017-04-08%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BHoshino%2C%20J.%20%26lt%3Bi%26gt%3Bet%20al.%26lt%3B%5C%2Fi%26gt%3B%20Unique%20hemoglobin%20A1c%20level%20distribution%20and%20its%20relationship%20with%20mortality%20in%20diabetic%20hemodialysis%20patients.%20%26lt%3Bi%26gt%3BKidney%20Int.%26lt%3B%5C%2Fi%26gt%3B%20%282017%29%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.kint.2017.02.008%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.kint.2017.02.008%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Unique%20hemoglobin%20A1c%20level%20distribution%20and%20its%20relationship%20with%20mortality%20in%20diabetic%20hemodialysis%20patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Junichi%22%2C%22lastName%22%3A%22Hoshino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Larkina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angelo%22%2C%22lastName%22%3A%22Karaboyas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%20A.%22%2C%22lastName%22%3A%22Bieber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoshifumi%22%2C%22lastName%22%3A%22Ubara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenmei%22%2C%22lastName%22%3A%22Takaichi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tadao%22%2C%22lastName%22%3A%22Akizawa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Takashi%22%2C%22lastName%22%3A%22Akiba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shunichi%22%2C%22lastName%22%3A%22Fukuhara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronald%20L.%22%2C%22lastName%22%3A%22Pisoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Akira%22%2C%22lastName%22%3A%22Saito%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruce%20M.%22%2C%22lastName%22%3A%22Robinson%22%7D%5D%2C%22abstractNote%22%3A%22Diabetic%20hemodialysis%20patients%20with%20hemoglobin%20A1c%20%28HbA1c%29%20levels%20below%206.5%25%20and%20over%208.0%25%20face%20a%20higher%20mortality%20risk.%20To%20determine%20the%20optimal%20glycemic%20control%20in%20Japanese%20patients%2C%20we%20examined%20the%20association%20between%20HbA1c%20and%20mortality%20in%202%2C300%20Japanese%20diabetic%20patients%20on%20maintenance%20hemodialysis%20with%20HbA1c%20levels%20determined%20at%20enrollment%20in%20the%20Japanese%20Dialysis%20Outcomes%20and%20Practice%20Patterns%20Study%20%28JDOPPS%29%20phases%202-5%2C%20using%20Cox%20regression%20analysis%20with%20adjustment%20for%20baseline%20age%2C%20sex%2C%20dialysis%20vintage%2C%2012%20general%20comorbidities%2C%20hemoglobin%2C%20albumin%20and%20creatinine%20levels%2C%20and%20insulin%20use%3B%20stratification%20by%20JDOPPS%20phase%3B%20and%20facility%20clustering%20taken%20into%20account.%20Overall%2C%2054%25%20of%20patients%20had%20HbA1c%20levels%20under%206.0%2C%20including%2014%25%20with%20HbA1c%20levels%20under%205.0.%20Insulin%20or%20oral%20diabetes%20medications%20were%20used%20less%20frequently%20in%20patients%20with%20higher%20HbA1c%20levels.%20The%20dependence%20of%20mortality%20on%20HbA1c%20level%20was%20U%20shaped.%20When%20the%20group%20with%20the%20lowest%20mortality%20%28HbA1c%206.0-7.0%29%20was%20used%20as%20a%20reference%2C%20the%20hazard%20ratios%20for%20HbA1c%20categories%20under%205.0%2C%205.0-6.0%2C%207.0%20to%20under%208.0%2C%20and%208.0%20and%20greater%20were%2C%20respectively%2C%201.56%20%2895%25%20confidence%20interval%2C%201.05-2.33%29%2C%201.26%20%280.92-1.71%29%2C%201.23%20%280.79-1.89%29%2C%20and%202.10%20%281.32-3.33%29%20in%20the%20adjusted%20model.%20The%20HbA1c%20level%20was%20not%20associated%20with%20self-reported%20hypoglycemic%20episodes%20in%20JDOPPS%20phase%205.%20The%20HbA1c%20levels%20in%20diabetic%20hemodialysis%20patients%20differ%20considerably%20between%20Japan%20and%20those%20reported%20from%20Western%20countries.%20Thus%2C%20our%20findings%20highlight%20the%20importance%20of%20domestic%20guidelines%20for%20glycemic%20control%20by%20race%20and%20country.%22%2C%22date%22%3A%22Apr%2008%2C%202017%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.kint.2017.02.008%22%2C%22ISSN%22%3A%221523-1755%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-04-21T09%3A56%3A44Z%22%7D%7D%2C%7B%22key%22%3A%228934TH9K%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Van%20Buren%20et%20al.%22%2C%22parsedDate%22%3A%222015-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BVan%20Buren%2C%20P.%20N.%20%26lt%3Bi%26gt%3Bet%20al.%26lt%3B%5C%2Fi%26gt%3B%20The%20Phosphate%20Binder%20Ferric%20Citrate%20and%20Mineral%20Metabolism%20and%20Inflammatory%20Markers%20in%20Maintenance%20Dialysis%20Patients%3A%20Results%20From%20Prespecified%20Analyses%20of%20a%20Randomized%20Clinical%20Trial.%20%26lt%3Bi%26gt%3BAm.%20J.%20Kidney%20Dis.%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B66%26lt%3B%5C%2Fb%26gt%3B%2C%20479%26%23x2013%3B488%20%282015%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Phosphate%20Binder%20Ferric%20Citrate%20and%20Mineral%20Metabolism%20and%20Inflammatory%20Markers%20in%20Maintenance%20Dialysis%20Patients%3A%20Results%20From%20Prespecified%20Analyses%20of%20a%20Randomized%20Clinical%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20N.%22%2C%22lastName%22%3A%22Van%20Buren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%20B.%22%2C%22lastName%22%3A%22Lewis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jamie%20P.%22%2C%22lastName%22%3A%22Dwyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Greene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Middleton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohammed%22%2C%22lastName%22%3A%22Sika%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kausik%22%2C%22lastName%22%3A%22Umanath%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josephine%20D.%22%2C%22lastName%22%3A%22Abraham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shahabul%20S.%22%2C%22lastName%22%3A%22Arfeen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isai%20G.%22%2C%22lastName%22%3A%22Bowline%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gil%22%2C%22lastName%22%3A%22Chernin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephen%20Z.%22%2C%22lastName%22%3A%22Fadem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simin%22%2C%22lastName%22%3A%22Goral%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Koury%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marvin%20V.%22%2C%22lastName%22%3A%22Sinsakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%20E.%22%2C%22lastName%22%3A%22Weiner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Collaborative%20Study%20Group%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Phosphate%20binders%20are%20the%20cornerstone%20of%20hyperphosphatemia%20management%20in%20dialysis%20patients.%20Ferric%20citrate%20is%20an%20iron-based%20oral%20phosphate%20binder%20that%20effectively%20lowers%20serum%20phosphorus%20levels.%5CnSTUDY%20DESIGN%3A%2052-week%2C%20open-label%2C%20phase%203%2C%20randomized%2C%20controlled%20trial%20for%20safety-profile%20assessment.%5CnSETTING%20%26amp%3B%20PARTICIPANTS%3A%20Maintenance%20dialysis%20patients%20with%20serum%20phosphorus%20levels%20%5Cu22656.0%20mg%5C%2FdL%20after%20washout%20of%20prior%20phosphate%20binders.%5CnINTERVENTION%3A%202%3A1%20randomization%20to%20ferric%20citrate%20or%20active%20control%20%28sevelamer%20carbonate%20and%5C%2For%20calcium%20acetate%29.%5CnOUTCOMES%3A%20Changes%20in%20mineral%20bone%20disease%2C%20protein-energy%20wasting%5C%2Finflammation%2C%20and%20occurrence%20of%20adverse%20events%20after%201%20year.%5CnMEASUREMENTS%3A%20Serum%20calcium%2C%20intact%20parathyroid%20hormone%2C%20phosphorus%2C%20aluminum%2C%20white%20blood%20cell%20count%2C%20percentage%20of%20lymphocytes%2C%20serum%20urea%20nitrogen%2C%20and%20bicarbonate.%5CnRESULTS%3A%20There%20were%20292%20participants%20randomly%20assigned%20to%20ferric%20citrate%2C%20and%20149%2C%20to%20active%20control.%20Groups%20were%20well%20matched.%20For%20mean%20changes%20from%20baseline%2C%20phosphorus%20levels%20decreased%20similarly%20in%20the%20ferric%20citrate%20and%20active%20control%20groups%20%28-2.04%5Cu00b11.99%20%5BSD%5D%20vs%20-2.18%5Cu00b12.25%20mg%5C%2FdL%2C%20respectively%3B%20P%3D0.9%29%3B%20serum%20calcium%20levels%20increased%20similarly%20in%20the%20ferric%20citrate%20and%20active%20control%20groups%20%280.22%5Cu00b10.90%20vs%200.31%5Cu00b10.95%20mg%5C%2FdL%3B%20P%3D0.2%29.%20Hypercalcemia%20occurred%20in%204%20participants%20receiving%20calcium%20acetate.%20Parathyroid%20hormone%20levels%20decreased%20similarly%20in%20the%20ferric%20citrate%20and%20active%20control%20groups%20%28-167.1%5Cu00b1399.8%20vs%20-152.7%5Cu00b1392.1%20pg%5C%2FmL%3B%20P%3D0.8%29.%20Serum%20albumin%2C%20bicarbonate%2C%20serum%20urea%20nitrogen%2C%20white%20blood%20cell%20count%20and%20percentage%20of%20lymphocytes%2C%20and%20aluminum%20values%20were%20similar%20between%20ferric%20citrate%20and%20active%20control.%20Total%20and%20low-density%20lipoprotein%20cholesterol%20levels%20were%20lower%20in%20participants%20receiving%20sevelamer%20than%20those%20receiving%20ferric%20citrate%20and%20calcium%20acetate.%20Fewer%20participants%20randomly%20assigned%20to%20ferric%20citrate%20had%20serious%20adverse%20events%20compared%20with%20active%20control.%5CnLIMITATIONS%3A%20Open-label%20study%2C%20few%20peritoneal%20dialysis%20patients.%5CnCONCLUSIONS%3A%20Ferric%20citrate%20was%20associated%20with%20similar%20phosphorus%20control%20compared%20to%20active%20control%2C%20with%20similar%20effects%20on%20markers%20of%20bone%20and%20mineral%20metabolism%20in%20dialysis%20patients.%20There%20was%20no%20evidence%20of%20protein-energy%20wasting%5C%2Finflammation%20or%20aluminum%20toxicity%2C%20and%20fewer%20participants%20randomly%20assigned%20to%20ferric%20citrate%20had%20serious%20adverse%20events.%20Ferric%20citrate%20is%20an%20effective%20phosphate%20binder%20with%20a%20safety%20profile%20comparable%20to%20sevelamer%20and%20calcium%20acetate.%22%2C%22date%22%3A%22Sep%202015%22%2C%22language%22%3A%22ENG%22%2C%22DOI%22%3A%2210.1053%5C%2Fj.ajkd.2015.03.013%22%2C%22ISSN%22%3A%221523-6838%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-12-02T06%3A19%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22W8FE8TEV%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lee%20et%20al.%22%2C%22parsedDate%22%3A%222015-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BLee%2C%20C.-T.%20%26lt%3Bi%26gt%3Bet%20al.%26lt%3B%5C%2Fi%26gt%3B%20Effect%20of%20oral%20ferric%20citrate%20on%20serum%20phosphorus%20in%20hemodialysis%20patients%3A%20multicenter%2C%20randomized%2C%20double-blind%2C%20placebo-controlled%20study.%20%26lt%3Bi%26gt%3BJ.%20Nephrol.%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B28%26lt%3B%5C%2Fb%26gt%3B%2C%20105%26%23x2013%3B113%20%282015%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effect%20of%20oral%20ferric%20citrate%20on%20serum%20phosphorus%20in%20hemodialysis%20patients%3A%20multicenter%2C%20randomized%2C%20double-blind%2C%20placebo-controlled%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chien-Te%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.-Wen%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shou-Shan%22%2C%22lastName%22%3A%22Chiang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yu-Sen%22%2C%22lastName%22%3A%22Peng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kuo-Hsiung%22%2C%22lastName%22%3A%22Shu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ming-Ju%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mai-Szu%22%2C%22lastName%22%3A%22Wu%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Hyperphosphatemia%20is%20a%20common%20complication%20in%20dialysis%20patients%20that%20can%20be%20treated%20by%20oral%20phosphate%20binders.%20We%20investigated%20the%20efficacy%20and%20safety%20of%20oral%20ferric%20citrate%20as%20a%20phosphate%20binder%20for%20Taiwanese%20patients%20with%20end%20stage%20renal%20disease%20and%20with%20hyperphosphatemia%20who%20were%20undergoing%20hemodialysis.%5CnMETHODS%3A%20This%20was%20a%20prospective%2C%20double-blind%2C%20placebo-controlled%2C%20randomized%20trial%20carried%20out%20in%205%20hospitals%20in%20Taiwan.%20Ferric%20citrate%20%284%20or%206%20g%5C%2Fday%29%20or%20placebo%20was%20administered%20for%2056%20days.%20Serum%20calcium%2C%20phosphorous%20levels%2C%20calcium%20%5Cu00d7%20phosphorus%20product%2C%20serum%20ferritin%20level%2C%20transferrin%20saturation%2C%20and%20adverse%20events%20were%20recorded.%5CnRESULTS%3A%20A%20total%20of%20166%20patients%20completed%20the%20trial.%20The%20placebo%20group%20had%20relatively%20constant%20serum%20data.%20Serum%20phosphorus%20declined%20significantly%20in%20the%206%20g%5C%2Fday%20group%20%28p%20%26lt%3B%200.05%20for%204%20and%208%20weeks%29%20and%20the%204%20g%5C%2Fday%20group%20%28p%20%26lt%3B%200.05%20for%204%20and%208%20weeks%29.%20There%20were%20similar%20changes%20in%20the%20calcium%20%5Cu00d7%20phosphorus%20product.%20The%20serum%20ferritin%20level%20increased%20significantly%20in%20the%206%20g%5C%2Fday%20group%20%28p%20%26lt%3B%200.05%29%20and%20the%204%20g%5C%2Fday%20group%20%28p%20%26lt%3B%200.05%29.%20There%20were%20similar%20changes%20in%20transferrin%20saturation.%20Most%20adverse%20events%20were%20mild%20to%20moderate%20and%20were%20comparable%20among%20the%20three%20groups.%5CnCONCLUSIONS%3A%20A%2056-day%20treatment%20with%20ferric%20citrate%20effectively%20controlled%20hyperphosphatemia%20and%20was%20well%20tolerated%20in%20maintenance%20hemodialysis%20patients.%20There%20were%20also%20moderate%20increases%20in%20serum%20ferritin%20and%20transferrin%20saturation.%22%2C%22date%22%3A%22Feb%202015%22%2C%22language%22%3A%22ENG%22%2C%22DOI%22%3A%2210.1007%5C%2Fs40620-014-0108-6%22%2C%22ISSN%22%3A%221724-6059%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-12-02T02%3A12%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22DIVD8H7R%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Yokoyama%20et%20al.%22%2C%22parsedDate%22%3A%222014-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BYokoyama%2C%20K.%20%26lt%3Bi%26gt%3Bet%20al.%26lt%3B%5C%2Fi%26gt%3B%20A%20randomized%20trial%20of%20JTT-751%20versus%20sevelamer%20hydrochloride%20in%20patients%20on%20hemodialysis.%20%26lt%3Bi%26gt%3BNephrol.%20Dial.%20Transplant.%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B29%26lt%3B%5C%2Fb%26gt%3B%2C%201053%26%23x2013%3B1060%20%282014%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20randomized%20trial%20of%20JTT-751%20versus%20sevelamer%20hydrochloride%20in%20patients%20on%20hemodialysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keitaro%22%2C%22lastName%22%3A%22Yokoyama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Takashi%22%2C%22lastName%22%3A%22Akiba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Masafumi%22%2C%22lastName%22%3A%22Fukagawa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Masaaki%22%2C%22lastName%22%3A%22Nakayama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenichi%22%2C%22lastName%22%3A%22Sawada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yuji%22%2C%22lastName%22%3A%22Kumagai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Glenn%20M.%22%2C%22lastName%22%3A%22Chertow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hideki%22%2C%22lastName%22%3A%22Hirakata%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20JTT-751%20is%20a%20novel%20phosphate%20binder%20containing%20ferric%20citrate%20as%20the%20active%20ingredient.%5CnMETHODS%3A%20In%20this%20Phase%203%2C%20multicenter%2C%20randomized%2C%20open-label%2C%20parallel-group%20study%2C%20we%20compared%20the%20efficacy%20and%20safety%20of%20JTT-751%20and%20sevelamer%20hydrochloride%20in%20patients%20undergoing%20hemodialysis.%20A%20total%20of%20230%20patients%20with%20a%20serum%20phosphate%20%5Cu22651.97%20and%20%26lt%3B3.23%20mmol%5C%2FL%20were%20randomized%20to%20JTT-751%20%28dose%20adjusted%20between%201.5%20and%206.0%20g%5C%2Fday%29%20or%20sevelamer%20hydrochloride%20%28dose%20adjusted%20between%203.0%20and%209.0%20g%5C%2Fday%29%20for%2012%20weeks.%20The%20primary%20outcome%20was%20change%20in%20serum%20phosphate%20from%20baseline%20to%20end%20of%20treatment.%20Secondary%20outcomes%20included%20the%20changes%20in%20corrected%20serum%20calcium%20and%20intact%20parathyroid%20hormone%20%28PTH%29.%20The%20changes%20in%20ferritin%2C%20transferrin%20saturation%20and%20erythropoiesis-stimulating%20agent%20dose%20were%20additional%20outcomes.%5CnRESULTS%3A%20Changes%20in%20serum%20phosphate%20at%20the%20end%20of%20treatment%20were%20-0.82%20mmol%5C%2FL%20in%20the%20JTT-751%20group%20and%20-0.78%20mmol%5C%2FL%20in%20the%20sevelamer%20group%2C%20establishing%20non-inferiority%20of%20JTT-751%20compared%20with%20sevelamer%20%28least%20squares%20mean%2C%20-0.03%20mmol%5C%2FL%3B%2095%25%20confidence%20interval%2C%20-0.13%20to%200.07%20mmol%5C%2FL%29.%20Corrected%20serum%20calcium%20increased%20and%20PTH%20decreased%20from%20baseline%20within%20both%20groups%3B%20changes%20between%20groups%20were%20similar.%20Gastrointestinal%20disorders%20were%20the%20most%20common%20adverse%20events%20in%20both%20groups%3B%20the%20incidence%20of%20diarrhea%20was%20higher%20in%20the%20JTT-751%20group%2C%20while%20constipation%20occurred%20frequently%20in%20the%20sevelamer%20group.%20Treatment%20with%20JTT-751%20resulted%20in%20significant%20relative%20increases%20in%20serum%20ferritin%20and%20transferrin%20saturation.%5CnCONCLUSIONS%3A%20Efficacy%20and%20safety%20of%20JTT-751%20was%20comparable%20to%20sevelamer%20in%20patients%20on%20hemodialysis%20with%20hyperphosphatemia.%20Differential%20adverse%20effects%20were%20observed%3B%20biochemical%20markers%20of%20iron%20status%20increased%20in%20patients%20treated%20with%20JTT-751.%5CnTRIAL%20REGISTRATION%20NUMBER%3A%20CTI-111433%20%28The%20Japan%20Pharmaceutical%20Information%20Center%20at%3A%20http%5C%2F%5C%2Fwww.clinicaltrials.jp%29.%20Date%20of%20registration%3A%207%20March%202011.%22%2C%22date%22%3A%22May%202014%22%2C%22language%22%3A%22ENG%22%2C%22DOI%22%3A%2210.1093%5C%2Fndt%5C%2Fgft483%22%2C%22ISSN%22%3A%221460-2385%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-12-02T01%3A55%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22T3S3Z4JM%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lewis%20et%20al.%22%2C%22parsedDate%22%3A%222015-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BLewis%2C%20J.%20B.%20%26lt%3Bi%26gt%3Bet%20al.%26lt%3B%5C%2Fi%26gt%3B%20Ferric%20Citrate%20Controls%20Phosphorus%20and%20Delivers%20Iron%20in%20Patients%20on%20Dialysis.%20%26lt%3Bi%26gt%3BJ%20Am%20Soc%20Nephrol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B26%26lt%3B%5C%2Fb%26gt%3B%2C%20493%26%23x2013%3B503%20%282015%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Ferric%20Citrate%20Controls%20Phosphorus%20and%20Delivers%20Iron%20in%20Patients%20on%20Dialysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%20B.%22%2C%22lastName%22%3A%22Lewis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohammed%22%2C%22lastName%22%3A%22Sika%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20J.%22%2C%22lastName%22%3A%22Koury%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peale%22%2C%22lastName%22%3A%22Chuang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerald%22%2C%22lastName%22%3A%22Schulman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20T.%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederick%20C.%22%2C%22lastName%22%3A%22Whittier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Douglas%20R.%22%2C%22lastName%22%3A%22Linfert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude%20M.%22%2C%22lastName%22%3A%22Galphin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Balaji%20P.%22%2C%22lastName%22%3A%22Athreya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20Kaldun%20Kaldun%22%2C%22lastName%22%3A%22Nossuli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ingrid%20J.%22%2C%22lastName%22%3A%22Chang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%20S.%22%2C%22lastName%22%3A%22Blumenthal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Manley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%22%2C%22lastName%22%3A%22Zeig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kotagal%20S.%22%2C%22lastName%22%3A%22Kant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Jose%22%2C%22lastName%22%3A%22Olivero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Greene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jamie%20P.%22%2C%22lastName%22%3A%22Dwyer%22%7D%5D%2C%22abstractNote%22%3A%22Patients%20on%20dialysis%20require%20phosphorus%20binders%20to%20prevent%20hyperphosphatemia%20and%20are%20iron%20deficient.%20We%20studied%20ferric%20citrate%20as%20a%20phosphorus%20binder%20and%20iron%20source.%20In%20this%20sequential%2C%20randomized%20trial%2C%20441%20subjects%20on%20dialysis%20were%20randomized%20to%20ferric%20citrate%20or%20active%20control%20in%20a%2052-week%20active%20control%20period%20followed%20by%20a%204-week%20placebo%20control%20period%2C%20in%20which%20subjects%20on%20ferric%20citrate%20who%20completed%20the%20active%20control%20period%20were%20rerandomized%20to%20ferric%20citrate%20or%20placebo.%20The%20primary%20analysis%20compared%20the%20mean%20change%20in%20phosphorus%20between%20ferric%20citrate%20and%20placebo%20during%20the%20placebo%20control%20period.%20A%20sequential%20gatekeeping%20strategy%20controlled%20study-wise%20type%201%20error%20for%20serum%20ferritin%2C%20transferrin%20saturation%2C%20and%20intravenous%20iron%20and%20erythropoietin-stimulating%20agent%20usage%20as%20prespecified%20secondary%20outcomes%20in%20the%20active%20control%20period.%20Ferric%20citrate%20controlled%20phosphorus%20compared%20with%20placebo%2C%20with%20a%20mean%20treatment%20difference%20of%20%5Cu22122.2%5Cu00b10.2%20mg%5C%2Fdl%20%28mean%5Cu00b1SEM%29%20%28P%26lt%3B0.001%29.%20Active%20control%20period%20phosphorus%20was%20similar%20between%20ferric%20citrate%20and%20active%20control%2C%20with%20comparable%20safety%20profiles.%20Subjects%20on%20ferric%20citrate%20achieved%20higher%20mean%20iron%20parameters%20%28ferritin%3D899%5Cu00b1488%20ng%5C%2Fml%20%5Bmean%5Cu00b1SD%5D%3B%20transferrin%20saturation%3D39%25%5Cu00b117%25%29%20versus%20subjects%20on%20active%20control%20%28ferritin%3D628%5Cu00b1367%20ng%5C%2Fml%20%5Bmean%5Cu00b1SD%5D%3B%20transferrin%20saturation%3D30%25%5Cu00b112%25%3B%20P%26lt%3B0.001%20for%20both%29.%20Subjects%20on%20ferric%20citrate%20received%20less%20intravenous%20elemental%20iron%20%28median%3D12.95%20mg%5C%2Fwk%20ferric%20citrate%3B%2026.88%20mg%5C%2Fwk%20active%20control%3B%20P%26lt%3B0.001%29%20and%20less%20erythropoietin-stimulating%20agent%20%28median%20epoetin-equivalent%20units%20per%20week%3A%205306%20units%5C%2Fwk%20ferric%20citrate%3B%206951%20units%5C%2Fwk%20active%20control%3B%20P%3D0.04%29.%20Hemoglobin%20levels%20were%20statistically%20higher%20on%20ferric%20citrate.%20Thus%2C%20ferric%20citrate%20is%20an%20efficacious%20and%20safe%20phosphate%20binder%20that%20increases%20iron%20stores%20and%20reduces%20intravenous%20iron%20and%20erythropoietin-stimulating%20agent%20use%20while%20maintaining%20hemoglobin.%22%2C%22date%22%3A%222015-2%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1681%5C%2FASN.2014020212%22%2C%22ISSN%22%3A%221046-6673%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC4310662%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-12-02T00%3A51%3A54Z%22%7D%7D%2C%7B%22key%22%3A%225UPJNZ26%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pennoyer%20and%20Bridgeman%22%2C%22parsedDate%22%3A%222015-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPennoyer%2C%20A.%20%26amp%3B%20Bridgeman%2C%20M.%20B.%20Ferric%20Citrate%20%28Auryxia%29%20for%20the%20Treatment%20of%20Hyperphosphatemia.%20%26lt%3Bi%26gt%3BP%20T%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B40%26lt%3B%5C%2Fb%26gt%3B%2C%20329%26%23x2013%3B339%20%282015%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Ferric%20Citrate%20%28Auryxia%29%20for%20the%20Treatment%20of%20Hyperphosphatemia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adam%22%2C%22lastName%22%3A%22Pennoyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%20Barna%22%2C%22lastName%22%3A%22Bridgeman%22%7D%5D%2C%22abstractNote%22%3A%22Ferric%20citrate%20%28Auryxia%29%20for%20the%20treatment%20of%20hyperphosphatemia%22%2C%22date%22%3A%222015-5%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%221052-1372%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC4422633%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-11-29T02%3A22%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22JHPWBFXZ%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPBF%26%23x5BF6%3B%26%23x9F61%3B%26%23x5BCC%3B%26%23x9326%3B%26%23x751F%3B%26%23x6280%3B.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fwww.pbf.com.tw%5C%2Fcht%5C%2Fresearch.php%3Fserial%3D1%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fwww.pbf.com.tw%5C%2Fcht%5C%2Fresearch.php%3Fserial%3D1%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22webpage%22%2C%22title%22%3A%22PBF%5Cu5bf6%5Cu9f61%5Cu5bcc%5Cu9326%5Cu751f%5Cu6280%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.pbf.com.tw%5C%2Fcht%5C%2Fresearch.php%3Fserial%3D1%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%228V4TNTHP%22%5D%2C%22dateModified%22%3A%222016-11-29T02%3A15%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22UWKS4D5N%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPBF%26%23x5BF6%3B%26%23x9F61%3B%26%23x5BCC%3B%26%23x9326%3B%26%23x751F%3B%26%23x6280%3B.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fwww.pbf.com.tw%5C%2Fcht%5C%2Fresearch.php%3Fserial%3D1%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fwww.pbf.com.tw%5C%2Fcht%5C%2Fresearch.php%3Fserial%3D1%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22webpage%22%2C%22title%22%3A%22PBF%5Cu5bf6%5Cu9f61%5Cu5bcc%5Cu9326%5Cu751f%5Cu6280%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.pbf.com.tw%5C%2Fcht%5C%2Fresearch.php%3Fserial%3D1%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-11-29T02%3A12%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22BT5V7MHC%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BAuryxia%2C%20Fexeric%2C%20Riona%2C%20ferric%20citrate%20%28JTT-751%2C%20KRX-0502%29%20-%20Product%20Profile%20-%20BioCentury.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fwww.biocentury.com%5C%2Fproducts%5C%2Fauryxia%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fwww.biocentury.com%5C%2Fproducts%5C%2Fauryxia%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22webpage%22%2C%22title%22%3A%22Auryxia%2C%20Fexeric%2C%20Riona%2C%20ferric%20citrate%20%28JTT-751%2C%20KRX-0502%29%20-%20Product%20Profile%20-%20BioCentury%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.biocentury.com%5C%2Fproducts%5C%2Fauryxia%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-11-29T02%3A11%3A58Z%22%7D%7D%2C%7B%22key%22%3A%2298SWKCEP%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3B%26lt%3Bi%26gt%3BRead%20%26%23x2018%3BToxicological%20Effects%20of%20Methylmercury%26%23x2019%3B%20at%20NAP.edu%26lt%3B%5C%2Fi%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22book%22%2C%22title%22%3A%22Read%20%5C%22Toxicological%20Effects%20of%20Methylmercury%5C%22%20at%20NAP.edu%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22Mercury%20is%20widespread%20in%20our%20environment.%20%20Methylmercury%2C%20one%20organic%20form%20of%20mercury%2C%20can%20accumulate%20up%20the%20aquatic%20food%20chain%20and%20lead%20to%20high%20concentrations%20in%20predatory%20fish.%20%20When%20consumed%20by%20humans%2C%20contaminated%20fish%20represent%20a%20public%20health%20risk.%20%5Cn%5CnCombustion%20processes%2C%20especially%20coal-fired%20power%20plants%2C%20are%20major%20sources%20of%20mercury%20contamination%20in%20the%20environment.%20%20The%20U.S.%20Environmental%20Protection%20Agency%20%28EPA%29%20is%20considering%20regulating%20mercury%20emissions%20from%20those%20plants.%20%5Cn%5CnToxicological%20Effects%20of%20Methylmercury%20reviews%20the%20health%20effects%20of%20methylmercury%20and%20discusses%20the%20estimation%20of%20mercury%20exposure%20from%20measured%20biomarkers%2C%20how%20differences%20between%20individuals%20affect%20mercury%20toxicity%2C%20and%20appropriate%20statistical%20methods%20for%20analysis%20of%20the%20data%20and%20thoroughly%20compares%20the%20epidemiological%20studies%20available%20on%20methylmercury.%20%20Included%20are%20discussions%20of%20current%20mercury%20levels%20on%20public%20health%20and%20a%20delineation%20of%20the%20scientific%20aspects%20and%20policy%20decisions%20involved%20in%20the%20regulation%20of%20mercury.%20%5Cn%5CnThis%20report%20is%20a%20valuable%20resource%20for%20individuals%20interested%20in%20the%20public%20health%20effects%20and%20regulation%20of%20mercury.%20%20The%20report%20also%20provides%20an%20excellent%20example%20of%20the%20implications%20of%20decisions%20in%20the%20risk%20assessment%20process%20for%20a%20larger%20audience.%22%2C%22date%22%3A%22%22%2C%22language%22%3A%22%22%2C%22ISBN%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nap.edu%5C%2Fread%5C%2F9899%5C%2Fchapter%5C%2F4%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-11-23T07%3A19%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22VMS685TR%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3B%26lt%3Bi%26gt%3BRead%20%26%23x2018%3BToxicological%20Effects%20of%20Methylmercury%26%23x2019%3B%20at%20NAP.edu%26lt%3B%5C%2Fi%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22book%22%2C%22title%22%3A%22Read%20%5C%22Toxicological%20Effects%20of%20Methylmercury%5C%22%20at%20NAP.edu%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22Mercury%20is%20widespread%20in%20our%20environment.%20%20Methylmercury%2C%20one%20organic%20form%20of%20mercury%2C%20can%20accumulate%20up%20the%20aquatic%20food%20chain%20and%20lead%20to%20high%20concentrations%20in%20predatory%20fish.%20%20When%20consumed%20by%20humans%2C%20contaminated%20fish%20represent%20a%20public%20health%20risk.%20%5Cn%5CnCombustion%20processes%2C%20especially%20coal-fired%20power%20plants%2C%20are%20major%20sources%20of%20mercury%20contamination%20in%20the%20environment.%20%20The%20U.S.%20Environmental%20Protection%20Agency%20%28EPA%29%20is%20considering%20regulating%20mercury%20emissions%20from%20those%20plants.%20%5Cn%5CnToxicological%20Effects%20of%20Methylmercury%20reviews%20the%20health%20effects%20of%20methylmercury%20and%20discusses%20the%20estimation%20of%20mercury%20exposure%20from%20measured%20biomarkers%2C%20how%20differences%20between%20individuals%20affect%20mercury%20toxicity%2C%20and%20appropriate%20statistical%20methods%20for%20analysis%20of%20the%20data%20and%20thoroughly%20compares%20the%20epidemiological%20studies%20available%20on%20methylmercury.%20%20Included%20are%20discussions%20of%20current%20mercury%20levels%20on%20public%20health%20and%20a%20delineation%20of%20the%20scientific%20aspects%20and%20policy%20decisions%20involved%20in%20the%20regulation%20of%20mercury.%20%5Cn%5CnThis%20report%20is%20a%20valuable%20resource%20for%20individuals%20interested%20in%20the%20public%20health%20effects%20and%20regulation%20of%20mercury.%20%20The%20report%20also%20provides%20an%20excellent%20example%20of%20the%20implications%20of%20decisions%20in%20the%20risk%20assessment%20process%20for%20a%20larger%20audience.%22%2C%22date%22%3A%22%22%2C%22language%22%3A%22%22%2C%22ISBN%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nap.edu%5C%2Fread%5C%2F9899%5C%2Fchapter%5C%2F4%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-11-23T07%3A19%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22F7SUZUS8%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pisoni%20and%20D%27Cruz%22%2C%22parsedDate%22%3A%222008-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPisoni%2C%20C.%20N.%20%26amp%3B%20D%26%23x2019%3BCruz%2C%20D.%20P.%20The%20safety%20of%20mycophenolate%20mofetil%20in%20pregnancy.%20%26lt%3Bi%26gt%3BExpert%20Opin%20Drug%20Saf%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B7%26lt%3B%5C%2Fb%26gt%3B%2C%20219%26%23x2013%3B222%20%282008%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20safety%20of%20mycophenolate%20mofetil%20in%20pregnancy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cecilia%20N.%22%2C%22lastName%22%3A%22Pisoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20P.%22%2C%22lastName%22%3A%22D%27Cruz%22%7D%5D%2C%22abstractNote%22%3A%22Mycophenolate%20mofetil%20%28MMF%29%20has%20proved%20to%20be%20a%20major%20addition%20to%20the%20therapeutic%20options%20for%20the%20treatment%20of%20multisystem%20autoimmune%20disorders.%20The%20majority%20of%20the%20autoimmune%20rheumatological%20diseases%20are%20more%20prevalent%20in%20women%20and%20they%20are%20often%20first%20diagnosed%20during%20childbearing%20age.%20MMF%20use%20during%20pregnancy%20is%20associated%20with%20an%20increased%20risk%20of%20malformations%20and%20first-trimester%20pregnancy%20loss.%20The%20most%20frequent%20malformations%20include%20external%20ear%20and%20other%20facial%20malformations%20such%20as%20cleft%20palate%20and%20lip.%20Therefore%20MMF%20should%20be%20avoided%20during%20pregnancy%20and%20safe%20contraceptive%20methods%20provided.%22%2C%22date%22%3A%22May%202008%22%2C%22language%22%3A%22ENG%22%2C%22DOI%22%3A%2210.1517%5C%2F14740338.7.3.219%22%2C%22ISSN%22%3A%221744-764X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-11-19T07%3A21%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22665KNHBV%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22%5Cu838a%5Cu6b66%5Cu9f8d%5Cu91ab%5Cu5e2b%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3B%26%23x838A%3B%26%23x6B66%3B%26%23x9F8D%3B%26%23x91AB%3B%26%23x5E2B%3B.%202016-17%20%26%23x7CD6%3B%26%23x5C3F%3B%26%23x75C5%3B%26%23x75C5%3B%26%23x4EBA%3B%26%23x6D41%3B%26%23x611F%3B%26%23x7684%3B%26%23x9810%3B%26%23x9632%3B%26%23x53CA%3B%26%23x6CE8%3B%26%23x610F%3B%26%23x4E8B%3B%26%23x9805%3B.%20%26%23x6B66%3B%26%23x9F8D%3B%26%23x91AB%3B%26%23x5E2B%3B%26%23x7684%3B%26%23x7532%3B%26%23x72C0%3B%26%23x817A%3B%26%23x53CA%3B%26%23x7CD6%3B%26%23x5C3F%3B%26%23x75C5%3B%26%23x885B%3B%26%23x6559%3B%26%23x7DB2%3B%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fwww.tmaker.org%5C%2F2016%5C%2F10%5C%2F2016-17-influenza-vaccine.html%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fwww.tmaker.org%5C%2F2016%5C%2F10%5C%2F2016-17-influenza-vaccine.html%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22blogPost%22%2C%22title%22%3A%222016-17%20%5Cu7cd6%5Cu5c3f%5Cu75c5%5Cu75c5%5Cu4eba%5Cu6d41%5Cu611f%5Cu7684%5Cu9810%5Cu9632%5Cu53ca%5Cu6ce8%5Cu610f%5Cu4e8b%5Cu9805%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22%5Cu838a%5Cu6b66%5Cu9f8d%5Cu91ab%5Cu5e2b%22%7D%5D%2C%22abstractNote%22%3A%222016-17%20%5Cu7cd6%5Cu5c3f%5Cu75c5%5Cu75c5%5Cu4eba%5Cu6d41%5Cu611f%5Cu7684%5Cu9810%5Cu9632%5Cu53ca%5Cu6ce8%5Cu610f%5Cu4e8b%5Cu9805%20%20%20%20%20%5Cu201d%20%5Cu8840%5Cu7cd6%5Cu82e5%5Cu662f%5Cu8d85%5Cu904e250%20mg%5C%2Fdl%5Cuff0c%5Cu514d%5Cu75ab%5Cu529b%5Cu5c31%5Cu6709%5Cu53ef%5Cu80fd%5Cu6703%5Cu4e0b%5Cu964d%5Cu3002%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu7cd6%5Cu5c3f%5Cu75c5%5Cu75c5%5Cu60a3%5Cu5982%5Cu4f55%5Cu5728%5Cu6d41%5Cu611f%5Cu5b63%5Cu7bc0%5Cu5b88%5Cu8b77%5Cu81ea%5Cu5df1%5Cu7684%5Cu5065%5Cu5eb7%5Cuff1f%20%20%5Cu771f%5Cu5fc3%5Cu60f3%5Cu8981%5Cu5b88%5Cu8b77%5Cu500b%5Cu4eba%5Cu6216%5Cu662f%5Cu5bb6%5Cu4eba%5Cu7684%5Cu5065%5Cu5eb7%5Cuff0c%20%20%5Cu53ef%5Cu4ee5%5Cu628a%5Cu300e%5Cu4e00%5Cu500b%5Cu53ef%5Cu4ee5%5Cu9810%5Cu9632%5Cu7684%5Cu75be%5Cu75c5%5Cu300f%5Cuff0c%20%20%5Cu8996%5Cu70ba%5Cu4e00%5Cu500b%5Cu4e8b%5Cu6545%5Cu4f86%5Cu770b%5Cu5f85...%22%2C%22blogTitle%22%3A%22%5Cu6b66%5Cu9f8d%5Cu91ab%5Cu5e2b%5Cu7684%5Cu7532%5Cu72c0%5Cu817a%5Cu53ca%5Cu7cd6%5Cu5c3f%5Cu75c5%5Cu885b%5Cu6559%5Cu7db2%22%2C%22date%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.tmaker.org%5C%2F2016%5C%2F10%5C%2F2016-17-influenza-vaccine.html%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-10-11T03%3A14%3A14Z%22%7D%7D%2C%7B%22key%22%3A%222CRXZ896%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22%5Cu838a%5Cu6b66%5Cu9f8d%5Cu91ab%5Cu5e2b%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3B%26%23x838A%3B%26%23x6B66%3B%26%23x9F8D%3B%26%23x91AB%3B%26%23x5E2B%3B.%202016-17%20%26%23x7CD6%3B%26%23x5C3F%3B%26%23x75C5%3B%26%23x75C5%3B%26%23x4EBA%3B%26%23x6D41%3B%26%23x611F%3B%26%23x7684%3B%26%23x9810%3B%26%23x9632%3B%26%23x53CA%3B%26%23x6CE8%3B%26%23x610F%3B%26%23x4E8B%3B%26%23x9805%3B.%20%26%23x6B66%3B%26%23x9F8D%3B%26%23x91AB%3B%26%23x5E2B%3B%26%23x7684%3B%26%23x7532%3B%26%23x72C0%3B%26%23x817A%3B%26%23x53CA%3B%26%23x7CD6%3B%26%23x5C3F%3B%26%23x75C5%3B%26%23x885B%3B%26%23x6559%3B%26%23x7DB2%3B%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fwww.tmaker.org%5C%2F2016%5C%2F10%5C%2F2016-17-influenza-vaccine.html%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fwww.tmaker.org%5C%2F2016%5C%2F10%5C%2F2016-17-influenza-vaccine.html%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22blogPost%22%2C%22title%22%3A%222016-17%20%5Cu7cd6%5Cu5c3f%5Cu75c5%5Cu75c5%5Cu4eba%5Cu6d41%5Cu611f%5Cu7684%5Cu9810%5Cu9632%5Cu53ca%5Cu6ce8%5Cu610f%5Cu4e8b%5Cu9805%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22%5Cu838a%5Cu6b66%5Cu9f8d%5Cu91ab%5Cu5e2b%22%7D%5D%2C%22abstractNote%22%3A%222016-17%20%5Cu7cd6%5Cu5c3f%5Cu75c5%5Cu75c5%5Cu4eba%5Cu6d41%5Cu611f%5Cu7684%5Cu9810%5Cu9632%5Cu53ca%5Cu6ce8%5Cu610f%5Cu4e8b%5Cu9805%20%20%20%20%20%5Cu201d%20%5Cu8840%5Cu7cd6%5Cu82e5%5Cu662f%5Cu8d85%5Cu904e250%20mg%5C%2Fdl%5Cuff0c%5Cu514d%5Cu75ab%5Cu529b%5Cu5c31%5Cu6709%5Cu53ef%5Cu80fd%5Cu6703%5Cu4e0b%5Cu964d%5Cu3002%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu7cd6%5Cu5c3f%5Cu75c5%5Cu75c5%5Cu60a3%5Cu5982%5Cu4f55%5Cu5728%5Cu6d41%5Cu611f%5Cu5b63%5Cu7bc0%5Cu5b88%5Cu8b77%5Cu81ea%5Cu5df1%5Cu7684%5Cu5065%5Cu5eb7%5Cuff1f%20%20%5Cu771f%5Cu5fc3%5Cu60f3%5Cu8981%5Cu5b88%5Cu8b77%5Cu500b%5Cu4eba%5Cu6216%5Cu662f%5Cu5bb6%5Cu4eba%5Cu7684%5Cu5065%5Cu5eb7%5Cuff0c%20%20%5Cu53ef%5Cu4ee5%5Cu628a%5Cu300e%5Cu4e00%5Cu500b%5Cu53ef%5Cu4ee5%5Cu9810%5Cu9632%5Cu7684%5Cu75be%5Cu75c5%5Cu300f%5Cuff0c%20%20%5Cu8996%5Cu70ba%5Cu4e00%5Cu500b%5Cu4e8b%5Cu6545%5Cu4f86%5Cu770b%5Cu5f85...%22%2C%22blogTitle%22%3A%22%5Cu6b66%5Cu9f8d%5Cu91ab%5Cu5e2b%5Cu7684%5Cu7532%5Cu72c0%5Cu817a%5Cu53ca%5Cu7cd6%5Cu5c3f%5Cu75c5%5Cu885b%5Cu6559%5Cu7db2%22%2C%22date%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.tmaker.org%5C%2F2016%5C%2F10%5C%2F2016-17-influenza-vaccine.html%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-10-11T03%3A14%3A14Z%22%7D%7D%2C%7B%22key%22%3A%22K3P83ZUV%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22%5Cu838a%5Cu6b66%5Cu9f8d%5Cu91ab%5Cu5e2b%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3B%26%23x838A%3B%26%23x6B66%3B%26%23x9F8D%3B%26%23x91AB%3B%26%23x5E2B%3B.%202016-17%20%26%23x7CD6%3B%26%23x5C3F%3B%26%23x75C5%3B%26%23x75C5%3B%26%23x4EBA%3B%26%23x6D41%3B%26%23x611F%3B%26%23x7684%3B%26%23x9810%3B%26%23x9632%3B%26%23x53CA%3B%26%23x6CE8%3B%26%23x610F%3B%26%23x4E8B%3B%26%23x9805%3B.%20%26%23x6B66%3B%26%23x9F8D%3B%26%23x91AB%3B%26%23x5E2B%3B%26%23x7684%3B%26%23x7532%3B%26%23x72C0%3B%26%23x817A%3B%26%23x53CA%3B%26%23x7CD6%3B%26%23x5C3F%3B%26%23x75C5%3B%26%23x885B%3B%26%23x6559%3B%26%23x7DB2%3B%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fwww.tmaker.org%5C%2F2016%5C%2F10%5C%2F2016-17-influenza-vaccine.html%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fwww.tmaker.org%5C%2F2016%5C%2F10%5C%2F2016-17-influenza-vaccine.html%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22blogPost%22%2C%22title%22%3A%222016-17%20%5Cu7cd6%5Cu5c3f%5Cu75c5%5Cu75c5%5Cu4eba%5Cu6d41%5Cu611f%5Cu7684%5Cu9810%5Cu9632%5Cu53ca%5Cu6ce8%5Cu610f%5Cu4e8b%5Cu9805%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22%5Cu838a%5Cu6b66%5Cu9f8d%5Cu91ab%5Cu5e2b%22%7D%5D%2C%22abstractNote%22%3A%222016-17%20%5Cu7cd6%5Cu5c3f%5Cu75c5%5Cu75c5%5Cu4eba%5Cu6d41%5Cu611f%5Cu7684%5Cu9810%5Cu9632%5Cu53ca%5Cu6ce8%5Cu610f%5Cu4e8b%5Cu9805%20%20%20%20%20%5Cu201d%20%5Cu8840%5Cu7cd6%5Cu82e5%5Cu662f%5Cu8d85%5Cu904e250%20mg%5C%2Fdl%5Cuff0c%5Cu514d%5Cu75ab%5Cu529b%5Cu5c31%5Cu6709%5Cu53ef%5Cu80fd%5Cu6703%5Cu4e0b%5Cu964d%5Cu3002%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cu7cd6%5Cu5c3f%5Cu75c5%5Cu75c5%5Cu60a3%5Cu5982%5Cu4f55%5Cu5728%5Cu6d41%5Cu611f%5Cu5b63%5Cu7bc0%5Cu5b88%5Cu8b77%5Cu81ea%5Cu5df1%5Cu7684%5Cu5065%5Cu5eb7%5Cuff1f%20%20%5Cu771f%5Cu5fc3%5Cu60f3%5Cu8981%5Cu5b88%5Cu8b77%5Cu500b%5Cu4eba%5Cu6216%5Cu662f%5Cu5bb6%5Cu4eba%5Cu7684%5Cu5065%5Cu5eb7%5Cuff0c%20%20%5Cu53ef%5Cu4ee5%5Cu628a%5Cu300e%5Cu4e00%5Cu500b%5Cu53ef%5Cu4ee5%5Cu9810%5Cu9632%5Cu7684%5Cu75be%5Cu75c5%5Cu300f%5Cuff0c%20%20%5Cu8996%5Cu70ba%5Cu4e00%5Cu500b%5Cu4e8b%5Cu6545%5Cu4f86%5Cu770b%5Cu5f85...%22%2C%22blogTitle%22%3A%22%5Cu6b66%5Cu9f8d%5Cu91ab%5Cu5e2b%5Cu7684%5Cu7532%5Cu72c0%5Cu817a%5Cu53ca%5Cu7cd6%5Cu5c3f%5Cu75c5%5Cu885b%5Cu6559%5Cu7db2%22%2C%22date%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.tmaker.org%5C%2F2016%5C%2F10%5C%2F2016-17-influenza-vaccine.html%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-10-11T03%3A14%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22WKUXQQQH%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Wang%20et%20al.%22%2C%22parsedDate%22%3A%221999-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BWang%2C%20M.%2C%20Guo%2C%20C.%20%26amp%3B%20Li%2C%20M.%20%5BA%20case-control%20study%20on%20the%20dietary%20risk%20factors%20of%20upper%20digestive%20tract%20cancer%5D.%20%26lt%3Bi%26gt%3BZhonghua%20Liu%20Xing%20Bing%20Xue%20Za%20Zhi%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B20%26lt%3B%5C%2Fb%26gt%3B%2C%2095%26%23x2013%3B97%20%281999%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BA%20case-control%20study%20on%20the%20dietary%20risk%20factors%20of%20upper%20digestive%20tract%20cancer%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Guo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Li%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20understand%20the%20effect%20of%20dietary%20factors%20in%20Yangzhong%2C%20Jiangsu%20Province-a%20high%20prevalence%20area%20in%20China.%5CnMETHODS%3A%20A%20case-control%20study%20on%20209%20cases%20of%20upper%20digestive%20tract%20cancer%20was%20conducted.%20There%20were%2068%20cases%20of%20esophageal%20cancer%2C%2069%20cases%20of%20cardiac%20cancer%20and%2072%20cases%20of%20other%20gastric%20cancers%20including%20129%20males%20and%2080%20females%20aged%2035-79%20under%20the%20study.%5CnRESULTS%3A%20It%20is%20revealed%20that%20intake%20of%20pickled%20vegetables%20increases%20the%20ORs%20of%20esophageal%2C%20cardiac%20and%20other%20gastric%20cancers%20%28OR%20%3D%202.82%2C%20OR%20%3D%205.17%2C%20OR%20%3D%202.92%2C%20respectively%29.%20It%20is%20also%20concluded%20that%20the%20intake%20of%20leftovers%20can%20elevate%20the%20ORs%20of%20esophageal%20and%20cardiac%20gastric%20cancer%20%28OR%20%3D%201.88%20and%20OR%20%3D%201.90%29%20and%20over%20consumption%20of%20salt%20also%20elevates%20the%20OR%20of%20cardiac%20cancer%20%28OR%20%3D%201.87%29.%20However%2C%20drinking%20green%20tea%20may%20decrease%20the%20ORs%20of%20esophageal%20and%20other%20gastric%20cancers%20%28OR%20%3D%200.20%20and%20OR%20%3D%200.28%29%20while%20fruits%20consumption%20may%20reduce%20the%20OR%20of%20esophageal%20cancers%20%28OR%20%3D%200.51%29.%5CnCONCLUSION%3A%20Tumors%20from%20upper%20digestive%20tract%20have%20some%20relations%20with%20diet%20factors%20but%20the%20effects%20vary%20with%20the%20differences%20of%20tumor%20sites%2C%20dose%20of%20exposure%20and%20area%2C%20etc.%22%2C%22date%22%3A%22Apr%201999%22%2C%22language%22%3A%22chi%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%220254-6450%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-08-05T08%3A25%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22WKHQJPFU%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Wu%20et%20al.%22%2C%22parsedDate%22%3A%222005-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BWu%2C%20V.-C.%2C%20Lin%2C%20S.-L.%2C%20Lin%2C%20S.-M.%20%26amp%3B%20Fang%2C%20C.-C.%20Treatment%20of%20baclofen%20overdose%20by%20haemodialysis%3A%20a%20pharmacokinetic%20study.%20%26lt%3Bi%26gt%3BNephrol.%20Dial.%20Transplant.%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B20%26lt%3B%5C%2Fb%26gt%3B%2C%20441%26%23x2013%3B443%20%282005%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Treatment%20of%20baclofen%20overdose%20by%20haemodialysis%3A%20a%20pharmacokinetic%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vin-Cent%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shuei-Liong%22%2C%22lastName%22%3A%22Lin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shu-Meng%22%2C%22lastName%22%3A%22Lin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cheng-Chung%22%2C%22lastName%22%3A%22Fang%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Feb%202005%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fndt%5C%2Fgfh297%22%2C%22ISSN%22%3A%220931-0509%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-07-01T07%3A27%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22RCX8HG76%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22El-Husseini%20et%20al.%22%2C%22parsedDate%22%3A%222011%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BEl-Husseini%2C%20A.%2C%20Sabucedo%2C%20A.%2C%20Lamarche%2C%20J.%2C%20Courville%2C%20C.%20%26amp%3B%20Peguero%2C%20A.%20Baclofen%20Toxicity%20in%20Patients%20with%20Advanced%20Nephropathy%3A%20Proposal%20for%20New%20Labeling.%20%26lt%3Bi%26gt%3BAmerican%20Journal%20of%20Nephrology%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B34%26lt%3B%5C%2Fb%26gt%3B%2C%20491%26%23x2013%3B495%20%282011%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Baclofen%20Toxicity%20in%20Patients%20with%20Advanced%20Nephropathy%3A%20Proposal%20for%20New%20Labeling%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amr%22%2C%22lastName%22%3A%22El-Husseini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alberto%22%2C%22lastName%22%3A%22Sabucedo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Lamarche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Craig%22%2C%22lastName%22%3A%22Courville%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alfredo%22%2C%22lastName%22%3A%22Peguero%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222011%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1159%5C%2F000333247%22%2C%22ISSN%22%3A%221421-9670%2C%200250-8095%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.karger.com%5C%2Fdoi%5C%2F10.1159%5C%2F000333247%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-07-01T03%3A13%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22ITW882UW%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Meillier%20et%20al.%22%2C%22parsedDate%22%3A%222015-07-29%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BMeillier%2C%20A.%20%26lt%3Bi%26gt%3Bet%20al.%26lt%3B%5C%2Fi%26gt%3B%20Baclofen-Induced%20Encephalopathy%20in%20End%20Stage%20Renal%20Disease%2C%20Baclofen-Induced%20Encephalopathy%20in%20End%20Stage%20Renal%20Disease.%20%26lt%3Bi%26gt%3BCase%20Reports%20in%20Medicine%2C%20Case%20Reports%20in%20Medicine%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B2015%2C%202015%26lt%3B%5C%2Fb%26gt%3B%2C%20e203936%20%282015%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Baclofen-Induced%20Encephalopathy%20in%20End%20Stage%20Renal%20Disease%2C%20Baclofen-Induced%20Encephalopathy%20in%20End%20Stage%20Renal%20Disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Meillier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cara%22%2C%22lastName%22%3A%22Heller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shyam%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Meillier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cara%22%2C%22lastName%22%3A%22Heller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shyam%22%2C%22lastName%22%3A%22Patel%22%7D%5D%2C%22abstractNote%22%3A%22Baclofen%20is%20a%20highly%20used%20centrally%20acting%20GABA%20agonist%20that%20continues%20to%20be%20an%20effective%20therapy%20for%20spasticity%20and%20chronic%20hiccups.%20The%20renally%20dependent%20excretion%20determines%20the%20circulating%20concentrations%20and%20guides%20effective%20dosing%20to%20decrease%20adverse%20reactions.%20Caution%20should%20be%20considered%20in%20administering%20baclofen%20to%20patients%20with%20decreased%20renal%20function.%20We%20present%20a%20patient%20with%20end%20stage%20renal%20disease%20on%20hemodialysis%20with%20recent%20baclofen%20ingestion%20who%20presented%20with%20toxic%20encephalopathy%20that%20was%20resolved%20with%20additional%20dialysis%20sessions.%2C%20Baclofen%20is%20a%20highly%20used%20centrally%20acting%20GABA%20agonist%20that%20continues%20to%20be%20an%20effective%20therapy%20for%20spasticity%20and%20chronic%20hiccups.%20The%20renally%20dependent%20excretion%20determines%20the%20circulating%20concentrations%20and%20guides%20effective%20dosing%20to%20decrease%20adverse%20reactions.%20Caution%20should%20be%20considered%20in%20administering%20baclofen%20to%20patients%20with%20decreased%20renal%20function.%20We%20present%20a%20patient%20with%20end%20stage%20renal%20disease%20on%20hemodialysis%20with%20recent%20baclofen%20ingestion%20who%20presented%20with%20toxic%20encephalopathy%20that%20was%20resolved%20with%20additional%20dialysis%20sessions.%22%2C%22date%22%3A%222015%5C%2F07%5C%2F29%2C%202015%5C%2F07%5C%2F29%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1155%5C%2F2015%5C%2F203936%2C%2010.1155%5C%2F2015%5C%2F203936%22%2C%22ISSN%22%3A%221687-9627%2C%201687-9627%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.hindawi.com%5C%2Fjournals%5C%2Fcrim%5C%2F2015%5C%2F203936%5C%2Fabs%5C%2F%2C%20http%3A%5C%2F%5C%2Fwww.hindawi.com%5C%2Fjournals%5C%2Fcrim%5C%2F2015%5C%2F203936%5C%2Fabs%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-07-01T02%3A19%3A45Z%22%7D%7D%2C%7B%22key%22%3A%227SNZ82WE%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mousavi%20et%20al.%22%2C%22parsedDate%22%3A%222012%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BMousavi%2C%20S.%20S.%20B.%2C%20Mousavi%2C%20M.%20B.%20%26amp%3B%20Motemednia%2C%20F.%20Baclofen-induced%20encephalopathy%20in%20patient%20with%20end%20stage%20renal%20disease%3A%20Two%20case%20reports.%20%26lt%3Bi%26gt%3BIndian%20J%20Nephrol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B22%26lt%3B%5C%2Fb%26gt%3B%2C%20210%26%23x2013%3B212%20%282012%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Baclofen-induced%20encephalopathy%20in%20patient%20with%20end%20stage%20renal%20disease%3A%20Two%20case%20reports%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20S.%20Beladi%22%2C%22lastName%22%3A%22Mousavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20Beladi%22%2C%22lastName%22%3A%22Mousavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Motemednia%22%7D%5D%2C%22abstractNote%22%3A%22We%20report%20two%20end%20stage%20renal%20disease%20%28ESRD%29%20patients%2C%20who%20rapidly%20developed%20neurotoxicity%20after%20taking%20baclofen%2C%20a%20centrally%20acting%20gamma-aminobutyric%20acid%20agonist.%20They%20presented%20to%20our%20hospital%20in%20a%20state%20of%20confusion.%20On%20physical%20examination%2C%20there%20were%20no%20focal%20neurological%20deficits%20and%20the%20remainder%20of%20the%20examination%20was%20also%20not%20diagnostic.%20Laboratory%20data%20were%20unremarkable.%20The%20consciousness%20improved%20with%20supportive%20treatment%20and%20intensive%20hemodialysis%20over%203-4%20days.%20In%20conclusion%2C%20physicians%20should%20be%20aware%20of%20the%20possibility%20of%20baclofen-induced%20neurotoxicity%20in%20patients%20with%20renal%20disease%2C%20especially%20in%20ESRD%20patients%20and%20it%20is%20necessary%20to%20avoid%20or%20reduce%20baclofen%20dosage%20in%20these%20patients.%22%2C%22date%22%3A%222012%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.4103%5C%2F0971-4065.98762%22%2C%22ISSN%22%3A%220971-4065%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC3459527%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-07-01T02%3A03%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22RGP3GAAJ%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3B%26%23x5A92%3B%26%23x9AD4%3B%26%23x5831%3B%26%23x5C0E%3B%20-%20%26%23x6F22%3B%26%23x8AFE%3B%26%23x5A01%3B%26%23x8A3A%3B%26%23x6240%3B.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fsites.google.com%5C%2Fsite%5C%2Fhanoclinic%5C%2Fwen%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fsites.google.com%5C%2Fsite%5C%2Fhanoclinic%5C%2Fwen%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22webpage%22%2C%22title%22%3A%22%5Cu5a92%5Cu9ad4%5Cu5831%5Cu5c0e%20-%20%5Cu6f22%5Cu8afe%5Cu5a01%5Cu8a3a%5Cu6240%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22%5Cu53f0%5Cu4e2d%20%5Cu897f%5Cu5c6f%20%5Cu6f22%5Cu8afe%5Cu5a01%20%5Cu5bb6%5Cu5ead%5Cu91ab%5Cu5b78%20%5Cu5bb6%5Cu91ab%5Cu79d1%20%20%5Cu8a3a%5Cu6240%20%5Cu75db%5Cu98a8%20%5Cu6212%5Cu83f8%20%5Cu7cd6%5Cu5c3f%5Cu75c5%20%5Cu9ad8%5Cu8840%5Cu58d3%20%5Cu6c23%5Cu5598%20%5Cu904e%5Cu654f%20%5Cu651d%5Cu8b77%5Cu817a%20%5Cu6210%5Cu4eba%20%5Cu5c0f%5Cu5152%20%5Cu611f%5Cu5192%20%5Cu767c%5Cu71d2%20%5Cu904e%5Cu654f%5Cu6027%5Cu9f3b%5Cu708e%20%5Cu6c23%5Cu5598%20%5Cu76ae%5Cu819a%5Cu7662%20%5Cu8541%5Cu9ebb%5Cu75b9%20%5Cu8178%5Cu80c3%5Cu708e%20%5Cu6d88%5Cu5316%5Cu6027%5Cu6f70%5Cu760d%20%5Cu80c3%5Cu6f70%5Cu760d%20%5Cu98df%5Cu9053%5Cu9006%5Cu6d41%20%5Cu9ad8%5Cu8840%5Cu58d3%20%5Cu7cd6%5Cu5c3f%5Cu75c5%20%5Cu9ad8%5Cu8840%5Cu8102%20%5Cu75db%5Cu98a8%20%5Cu6ebc%5Cu75b9%20%5Cu8db3%5Cu766c%20%5Cu76ae%5Cu819a%5Cu75c5%20%5Cu9999%5Cu6e2f%5Cu8173%20%5Cu7126%5Cu616e%20%5Cu5931%5Cu7720%20%5Cu8eab%5Cu5fc3%5Cu75c7%20%5Cu6e1b%5Cu91cd%20%5Cu6212%5Cu83f8%20%5Cu6210%5Cu4eba%5Cu5065%5Cu6aa2%20%5Cu5152%5Cu7ae5%20%5Cu9810%5Cu9632%5Cu6ce8%5Cu5c04%20B%5Cu578b%5Cu809d%5Cu708e%5Cu8ffd%5Cu8e64%20C%5Cu578b%5Cu809d%5Cu708e%20%5Cu9a57%5Cu8840%20%5Cu62bd%5Cu8840%5Cu6aa2%5Cu67e5%20%5Cu5c3f%5Cu6db2%5Cu6aa2%5Cu67e5%20%5Cu7cde%5Cu4fbf%5Cu6aa2%5Cu67e5%20%5Cu6210%5Cu4eba%20%5Cu5152%5Cu7ae5%20%5Cu5065%5Cu5eb7%5Cu6aa2%5Cu67e5%5Cu8d85%5Cu97f3%5Cu6ce2%20%5Cu5fc3%5Cu96fb%5Cu5716%20%5Cu5a5a%5Cu524d%5Cu5065%5Cu6aa2%20%5Cu5c3c%5Cu53e4%5Cu6e05%20%5Cu6212%5Cu5fc5%5Cu9069%20%5Cu6212%5Cu83f8%5Cu85e5%20%5Cu7532%5Cu72c0%5Cu817a%20%5Cu7532%5Cu72c0%5Cu817a%5Cu529f%5Cu80fd%5Cu4ea2%5Cu9032%20%5Cu7532%5Cu72c0%5Cu817a%5Cu529f%5Cu80fd%5Cu4f4e%5Cu4e0b%20%5Cu6027%5Cu529f%5Cu80fd%5Cu969c%5Cu7919%20%5Cu5b50%5Cu5bae%5Cu9838%5Cu75ab%5Cu82d7%20%5Cu5b50%5Cu5bae%5Cu9838%5Cu764c%5Cu75ab%5Cu82d7%20%5Cu80ba%5Cu708e%5Cu75ab%5Cu82d7%20%5Cu6d41%5Cu611f%5Cu75ab%5Cu82d7%20%5Cu516c%5Cu8cbb%20%5Cu81ea%5Cu8cbb%22%2C%22date%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fsites.google.com%5C%2Fsite%5C%2Fhanoclinic%5C%2Fwen%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-01-05T00%3A03%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22JBZI4T22%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3B%26%23x5A92%3B%26%23x9AD4%3B%26%23x5831%3B%26%23x5C0E%3B%20-%20%26%23x6F22%3B%26%23x8AFE%3B%26%23x5A01%3B%26%23x8A3A%3B%26%23x6240%3B.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fsites.google.com%5C%2Fsite%5C%2Fhanoclinic%5C%2Fwen%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fsites.google.com%5C%2Fsite%5C%2Fhanoclinic%5C%2Fwen%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22webpage%22%2C%22title%22%3A%22%5Cu5a92%5Cu9ad4%5Cu5831%5Cu5c0e%20-%20%5Cu6f22%5Cu8afe%5Cu5a01%5Cu8a3a%5Cu6240%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22%5Cu53f0%5Cu4e2d%20%5Cu897f%5Cu5c6f%20%5Cu6f22%5Cu8afe%5Cu5a01%20%5Cu5bb6%5Cu5ead%5Cu91ab%5Cu5b78%20%5Cu5bb6%5Cu91ab%5Cu79d1%20%20%5Cu8a3a%5Cu6240%20%5Cu75db%5Cu98a8%20%5Cu6212%5Cu83f8%20%5Cu7cd6%5Cu5c3f%5Cu75c5%20%5Cu9ad8%5Cu8840%5Cu58d3%20%5Cu6c23%5Cu5598%20%5Cu904e%5Cu654f%20%5Cu651d%5Cu8b77%5Cu817a%20%5Cu6210%5Cu4eba%20%5Cu5c0f%5Cu5152%20%5Cu611f%5Cu5192%20%5Cu767c%5Cu71d2%20%5Cu904e%5Cu654f%5Cu6027%5Cu9f3b%5Cu708e%20%5Cu6c23%5Cu5598%20%5Cu76ae%5Cu819a%5Cu7662%20%5Cu8541%5Cu9ebb%5Cu75b9%20%5Cu8178%5Cu80c3%5Cu708e%20%5Cu6d88%5Cu5316%5Cu6027%5Cu6f70%5Cu760d%20%5Cu80c3%5Cu6f70%5Cu760d%20%5Cu98df%5Cu9053%5Cu9006%5Cu6d41%20%5Cu9ad8%5Cu8840%5Cu58d3%20%5Cu7cd6%5Cu5c3f%5Cu75c5%20%5Cu9ad8%5Cu8840%5Cu8102%20%5Cu75db%5Cu98a8%20%5Cu6ebc%5Cu75b9%20%5Cu8db3%5Cu766c%20%5Cu76ae%5Cu819a%5Cu75c5%20%5Cu9999%5Cu6e2f%5Cu8173%20%5Cu7126%5Cu616e%20%5Cu5931%5Cu7720%20%5Cu8eab%5Cu5fc3%5Cu75c7%20%5Cu6e1b%5Cu91cd%20%5Cu6212%5Cu83f8%20%5Cu6210%5Cu4eba%5Cu5065%5Cu6aa2%20%5Cu5152%5Cu7ae5%20%5Cu9810%5Cu9632%5Cu6ce8%5Cu5c04%20B%5Cu578b%5Cu809d%5Cu708e%5Cu8ffd%5Cu8e64%20C%5Cu578b%5Cu809d%5Cu708e%20%5Cu9a57%5Cu8840%20%5Cu62bd%5Cu8840%5Cu6aa2%5Cu67e5%20%5Cu5c3f%5Cu6db2%5Cu6aa2%5Cu67e5%20%5Cu7cde%5Cu4fbf%5Cu6aa2%5Cu67e5%20%5Cu6210%5Cu4eba%20%5Cu5152%5Cu7ae5%20%5Cu5065%5Cu5eb7%5Cu6aa2%5Cu67e5%5Cu8d85%5Cu97f3%5Cu6ce2%20%5Cu5fc3%5Cu96fb%5Cu5716%20%5Cu5a5a%5Cu524d%5Cu5065%5Cu6aa2%20%5Cu5c3c%5Cu53e4%5Cu6e05%20%5Cu6212%5Cu5fc5%5Cu9069%20%5Cu6212%5Cu83f8%5Cu85e5%20%5Cu7532%5Cu72c0%5Cu817a%20%5Cu7532%5Cu72c0%5Cu817a%5Cu529f%5Cu80fd%5Cu4ea2%5Cu9032%20%5Cu7532%5Cu72c0%5Cu817a%5Cu529f%5Cu80fd%5Cu4f4e%5Cu4e0b%20%5Cu6027%5Cu529f%5Cu80fd%5Cu969c%5Cu7919%20%5Cu5b50%5Cu5bae%5Cu9838%5Cu75ab%5Cu82d7%20%5Cu5b50%5Cu5bae%5Cu9838%5Cu764c%5Cu75ab%5Cu82d7%20%5Cu80ba%5Cu708e%5Cu75ab%5Cu82d7%20%5Cu6d41%5Cu611f%5Cu75ab%5Cu82d7%20%5Cu516c%5Cu8cbb%20%5Cu81ea%5Cu8cbb%22%2C%22date%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fsites.google.com%5C%2Fsite%5C%2Fhanoclinic%5C%2Fwen%22%2C%22language%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-01-05T00%3A03%3A03Z%22%7D%7D%2C%7B%22key%22%3A%222QFRVJ5V%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22National%20Kidney%20Foundation%22%2C%22parsedDate%22%3A%222015-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BNational%20Kidney%20Foundation.%20KDOQI%20Clinical%20Practice%20Guideline%20for%20Hemodialysis%20Adequacy%3A%202015%20Update.%20%26lt%3Bi%26gt%3BAm.%20J.%20Kidney%20Dis.%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B66%26lt%3B%5C%2Fb%26gt%3B%2C%20884%26%23x2013%3B930%20%282015%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22KDOQI%20Clinical%20Practice%20Guideline%20for%20Hemodialysis%20Adequacy%3A%202015%20Update%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22National%20Kidney%20Foundation%22%7D%5D%2C%22abstractNote%22%3A%22The%20National%20Kidney%20Foundation%26%23039%3Bs%20Kidney%20Disease%20Outcomes%20Quality%20Initiative%20%28KDOQI%29%20has%20provided%20evidence-based%20guidelines%20for%20all%20stages%20of%20chronic%20kidney%20disease%20%28CKD%29%20and%20related%20complications%20since%201997.%20The%202015%20update%20of%20the%20KDOQI%20Clinical%20Practice%20Guideline%20for%20Hemodialysis%20Adequacy%20is%20intended%20to%20assist%20practitioners%20caring%20for%20patients%20in%20preparation%20for%20and%20during%20hemodialysis.%20The%20literature%20reviewed%20for%20this%20update%20includes%20clinical%20trials%20and%20observational%20studies%20published%20between%202000%20and%20March%202014.%20New%20topics%20include%20high-frequency%20hemodialysis%20and%20risks%3B%20prescription%20flexibility%20in%20initiation%20timing%2C%20frequency%2C%20duration%2C%20and%20ultrafiltration%20rate%3B%20and%20more%20emphasis%20on%20volume%20and%20blood%20pressure%20control.%20Appraisal%20of%20the%20quality%20of%20the%20evidence%20and%20the%20strength%20of%20recommendations%20followed%20the%20Grading%20of%20Recommendation%20Assessment%2C%20Development%2C%20and%20Evaluation%20%28GRADE%29%20approach.%20Limitations%20of%20the%20evidence%20are%20discussed%20and%20specific%20suggestions%20are%20provided%20for%20future%20research.%22%2C%22date%22%3A%22Nov%202015%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1053%5C%2Fj.ajkd.2015.07.015%22%2C%22ISSN%22%3A%221523-6838%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222015-12-23T07%3A08%3A28Z%22%7D%7D%2C%7B%22key%22%3A%22N3KHVMNC%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bailie%20et%20al.%22%2C%22parsedDate%22%3A%222015-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BBailie%2C%20G.%20R.%20%26lt%3Bi%26gt%3Bet%20al.%26lt%3B%5C%2Fi%26gt%3B%20Data%20from%20the%20Dialysis%20Outcomes%20and%20Practice%20Patterns%20Study%20validate%20an%20association%20between%20high%20intravenous%20iron%20doses%20and%20mortality.%20%26lt%3Bi%26gt%3BKidney%20Int%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B87%26lt%3B%5C%2Fb%26gt%3B%2C%20162%26%23x2013%3B168%20%282015%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Data%20from%20the%20Dialysis%20Outcomes%20and%20Practice%20Patterns%20Study%20validate%20an%20association%20between%20high%20intravenous%20iron%20doses%20and%20mortality%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%20R.%22%2C%22lastName%22%3A%22Bailie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Larkina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20A.%22%2C%22lastName%22%3A%22Goodkin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yun%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronald%20L.%22%2C%22lastName%22%3A%22Pisoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%22%2C%22lastName%22%3A%22Bieber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nancy%22%2C%22lastName%22%3A%22Mason%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lin%22%2C%22lastName%22%3A%22Tong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesco%22%2C%22lastName%22%3A%22Locatelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20R.%22%2C%22lastName%22%3A%22Marshall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Masaaki%22%2C%22lastName%22%3A%22Inaba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruce%20M.%22%2C%22lastName%22%3A%22Robinson%22%7D%5D%2C%22abstractNote%22%3A%22Intravenous%20%28IV%29%20iron%20is%20required%20for%20optimal%20management%20of%20anemia%20in%20the%20majority%20of%20hemodialysis%20%28HD%29%20patients.%20While%20IV%20iron%20prescription%20has%20increased%20over%20time%2C%20the%20best%20dosing%20strategy%20is%20unknown%20and%20any%20effect%20of%20IV%20iron%20on%20survival%20is%20unclear.%20Here%20we%20used%20adjusted%20Cox%20regression%20to%20analyze%20associations%20between%20IV%20iron%20dose%20and%20clinical%20outcomes%20in%2032%2C435%20HD%20patients%20in%2012%20countries%20from%202002%20to%202011%20in%20the%20Dialysis%20Outcomes%20and%20Practice%20Patterns%20Study.%20The%20primary%20exposure%20was%20total%20prescribed%20IV%20iron%20dose%20over%20the%20first%204%20months%20in%20the%20study%2C%20expressed%20as%20an%20average%20dose%5C%2Fmonth.%20Compared%20with%20100%5Cu2013199%20mg%5C%2Fmonth%20%28the%20most%20common%20dose%20range%29%2C%20case-mix-adjusted%20mortality%20was%20similar%20for%20the%200%2C%201%5Cu201399%2C%20and%20200%5Cu2013299%20mg%5C%2Fmonth%20categories%20but%20significantly%20higher%20for%20the%20300%5Cu2013399%20mg%5C%2Fmonth%20%28HR%20of%201.13%2C%2095%25%20CI%20of%201.00%5Cu20131.27%29%20and%20400%20mg%5C%2Fmonth%20or%20more%20%28HR%20of%201.18%2C%2095%25%20CI%20of%201.07%5Cu20131.30%29%20groups.%20Convergent%20validity%20was%20proved%20by%20an%20instrumental%20variable%20analysis%2C%20using%20HD%20facility%20as%20the%20instrument%2C%20and%20by%20an%20analysis%20expressing%20IV%20iron%20dose%5C%2Fkg%20body%20weight.%20Associations%20with%20cause-specific%20mortality%20%28cardiovascular%2C%20infectious%2C%20and%20other%29%20were%20generally%20similar%20to%20those%20for%20all-cause%20mortality.%20The%20hospitalization%20risk%20was%20elevated%20among%20patients%20receiving%20300%20mg%5C%2Fmonth%20or%20more%20compared%20with%20100%5Cu2013199%20mg%5C%2Fmonth%20%28HR%20of%201.12%2C%2095%25%20CI%20of%201.07%5Cu20131.18%29.%20In%20light%20of%20these%20associations%2C%20a%20well-powered%20clinical%20trial%20to%20evaluate%20the%20safety%20of%20different%20IV%20iron-dosing%20strategies%20in%20HD%20patients%20is%20urgently%20needed.%22%2C%22date%22%3A%22January%202015%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fki.2014.275%22%2C%22ISSN%22%3A%220085-2538%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.nature.com%5C%2Fki%5C%2Fjournal%5C%2Fv87%5C%2Fn1%5C%2Ffull%5C%2Fki2014275a.html%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222015-11-13T01%3A33%3A03Z%22%7D%7D%2C%7B%22key%22%3A%227GX5AVNH%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bailie%20et%20al.%22%2C%22parsedDate%22%3A%222015-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BBailie%2C%20G.%20R.%20%26lt%3Bi%26gt%3Bet%20al.%26lt%3B%5C%2Fi%26gt%3B%20Data%20from%20the%20Dialysis%20Outcomes%20and%20Practice%20Patterns%20Study%20validate%20an%20association%20between%20high%20intravenous%20iron%20doses%20and%20mortality.%20%26lt%3Bi%26gt%3BKidney%20Int%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B87%26lt%3B%5C%2Fb%26gt%3B%2C%20162%26%23x2013%3B168%20%282015%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Data%20from%20the%20Dialysis%20Outcomes%20and%20Practice%20Patterns%20Study%20validate%20an%20association%20between%20high%20intravenous%20iron%20doses%20and%20mortality%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%20R.%22%2C%22lastName%22%3A%22Bailie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Larkina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20A.%22%2C%22lastName%22%3A%22Goodkin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yun%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronald%20L.%22%2C%22lastName%22%3A%22Pisoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%22%2C%22lastName%22%3A%22Bieber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nancy%22%2C%22lastName%22%3A%22Mason%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lin%22%2C%22lastName%22%3A%22Tong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesco%22%2C%22lastName%22%3A%22Locatelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20R.%22%2C%22lastName%22%3A%22Marshall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Masaaki%22%2C%22lastName%22%3A%22Inaba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruce%20M.%22%2C%22lastName%22%3A%22Robinson%22%7D%5D%2C%22abstractNote%22%3A%22Intravenous%20%28IV%29%20iron%20is%20required%20for%20optimal%20management%20of%20anemia%20in%20the%20majority%20of%20hemodialysis%20%28HD%29%20patients.%20While%20IV%20iron%20prescription%20has%20increased%20over%20time%2C%20the%20best%20dosing%20strategy%20is%20unknown%20and%20any%20effect%20of%20IV%20iron%20on%20survival%20is%20unclear.%20Here%20we%20used%20adjusted%20Cox%20regression%20to%20analyze%20associations%20between%20IV%20iron%20dose%20and%20clinical%20outcomes%20in%2032%2C435%20HD%20patients%20in%2012%20countries%20from%202002%20to%202011%20in%20the%20Dialysis%20Outcomes%20and%20Practice%20Patterns%20Study.%20The%20primary%20exposure%20was%20total%20prescribed%20IV%20iron%20dose%20over%20the%20first%204%20months%20in%20the%20study%2C%20expressed%20as%20an%20average%20dose%5C%2Fmonth.%20Compared%20with%20100%5Cu2013199%20mg%5C%2Fmonth%20%28the%20most%20common%20dose%20range%29%2C%20case-mix-adjusted%20mortality%20was%20similar%20for%20the%200%2C%201%5Cu201399%2C%20and%20200%5Cu2013299%20mg%5C%2Fmonth%20categories%20but%20significantly%20higher%20for%20the%20300%5Cu2013399%20mg%5C%2Fmonth%20%28HR%20of%201.13%2C%2095%25%20CI%20of%201.00%5Cu20131.27%29%20and%20400%20mg%5C%2Fmonth%20or%20more%20%28HR%20of%201.18%2C%2095%25%20CI%20of%201.07%5Cu20131.30%29%20groups.%20Convergent%20validity%20was%20proved%20by%20an%20instrumental%20variable%20analysis%2C%20using%20HD%20facility%20as%20the%20instrument%2C%20and%20by%20an%20analysis%20expressing%20IV%20iron%20dose%5C%2Fkg%20body%20weight.%20Associations%20with%20cause-specific%20mortality%20%28cardiovascular%2C%20infectious%2C%20and%20other%29%20were%20generally%20similar%20to%20those%20for%20all-cause%20mortality.%20The%20hospitalization%20risk%20was%20elevated%20among%20patients%20receiving%20300%20mg%5C%2Fmonth%20or%20more%20compared%20with%20100%5Cu2013199%20mg%5C%2Fmonth%20%28HR%20of%201.12%2C%2095%25%20CI%20of%201.07%5Cu20131.18%29.%20In%20light%20of%20these%20associations%2C%20a%20well-powered%20clinical%20trial%20to%20evaluate%20the%20safety%20of%20different%20IV%20iron-dosing%20strategies%20in%20HD%20patients%20is%20urgently%20needed.%22%2C%22date%22%3A%22January%202015%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fki.2014.275%22%2C%22ISSN%22%3A%220085-2538%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.nature.com%5C%2Fki%5C%2Fjournal%5C%2Fv87%5C%2Fn1%5C%2Ffull%5C%2Fki2014275a.html%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222015-11-13T01%3A27%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22BJZDPKAT%22%2C%22library%22%3A%7B%22id%22%3A2147300%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Weiss%20and%20Kronenberg%22%2C%22parsedDate%22%3A%222015-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%202%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BWeiss%2C%20G.%20%26amp%3B%20Kronenberg%2C%20F.%20Intravenous%20iron%20administration%3A%20new%20observations%20and%20time%20for%20the%20next%20steps.%20%26lt%3Bi%26gt%3BKidney%20Int%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bb%26gt%3B87%26lt%3B%5C%2Fb%26gt%3B%2C%2010%26%23x2013%3B12%20%282015%29.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Intravenous%20iron%20administration%3A%20new%20observations%20and%20time%20for%20the%20next%20steps%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00fcnter%22%2C%22lastName%22%3A%22Weiss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%22%2C%22lastName%22%3A%22Kronenberg%22%7D%5D%2C%22abstractNote%22%3A%22In%20this%20issue%20of%20Kidney%20International%2C%20the%20Dialysis%20Outcomes%20and%20Practice%20Patterns%20Study%20reports%20that%20hemodialysis%20patients%20with%20monthly%20intravenous%20iron%20supplementation%20of%20300%5Cu2013399%20mg%20or%20400%20mg%20had%20a%2013%20or%2018%25%20higher%20risk%20of%20dying%2C%20respectively%2C%20compared%20with%20those%20receiving%20100%5Cu2013199%20mg%20per%20month%2C%20with%20no%20obvious%20differences%20in%20cause-specific%20mortalities.%20This%20study%20supports%20that%20randomized%20controlled%20trials%20are%20urgently%20needed%20to%20identify%20optimized%20iron%20supplementation%20strategies%20for%20anemic%20dialysis%20patients.%22%2C%22date%22%3A%22January%202015%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fki.2014.324%22%2C%22ISSN%22%3A%220085-2538%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.nature.com%5C%2Fki%5C%2Fjournal%5C%2Fv87%5C%2Fn1%5C%2Ffull%5C%2Fki2014324a.html%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222015-11-13T01%3A26%3A01Z%22%7D%7D%5D%7D
1.
Lindley, M. C. & Kim, D. K. Increasing Protection of Dialysis Patients against Influenza. CJASN 13, 1624–1626 (2018).
1.
Miskulin, D. C. et al. High-Dose Seasonal Influenza Vaccine in Patients Undergoing Dialysis. CJASN 13, 1703–1711 (2018).
1.
Schwartz, G. J. & Work, D. F. Measurement and Estimation of GFR in Children and Adolescents. CJASN 4, 1832–1843 (2009).
1.
Patel, N., Dalal, P. & Panesar, M. Dialysis disequilibrium syndrome: a narrative review. Semin Dial 21, 493–498 (2008).
1.
Zepeda-Orozco, D. & Quigley, R. Dialysis disequilibrium syndrome. Pediatr Nephrol 27, 2205–2211 (2012).
1.
Turner, J. M. & Peixoto, A. J. Blood pressure targets for hemodialysis patients. Kidney International 92, 816–823 (2017).
1.
Younathan, C. M., Kaude, J. V., Cook, M. D., Shaw, G. S. & Peterson, J. C. Dialysis is not indicated immediately after administration of nonionic contrast agents in patients with end-stage renal disease treated by maintenance dialysis. AJR Am J Roentgenol 163, 969–971 (1994).
1.
Niscola, P. et al. The use of major analgesics in patients with renal dysfunction. Curr Drug Targets 11, 752–758 (2010).
1.
Tawfic, Q. A. & Bellingham, G. Postoperative pain management in patients with chronic kidney disease. J Anaesthesiol Clin Pharmacol 31, 6–13 (2015).
1.
Van Buren, P. N. et al. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial. Am. J. Kidney Dis. 66, 479–488 (2015).
1.
Lee, C.-T. et al. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study. J. Nephrol. 28, 105–113 (2015).
1.
Yokoyama, K. et al. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol. Dial. Transplant. 29, 1053–1060 (2014).
1.
Lewis, J. B. et al. Ferric Citrate Controls Phosphorus and Delivers Iron in Patients on Dialysis. J Am Soc Nephrol 26, 493–503 (2015).
1.
Pennoyer, A. & Bridgeman, M. B. Ferric Citrate (Auryxia) for the Treatment of Hyperphosphatemia. P T 40, 329–339 (2015).
1.
Read ‘Toxicological Effects of Methylmercury’ at NAP.edu.
1.
Read ‘Toxicological Effects of Methylmercury’ at NAP.edu.
1.
Pisoni, C. N. & D’Cruz, D. P. The safety of mycophenolate mofetil in pregnancy. Expert Opin Drug Saf 7, 219–222 (2008).
1.
Wang, M., Guo, C. & Li, M. [A case-control study on the dietary risk factors of upper digestive tract cancer]. Zhonghua Liu Xing Bing Xue Za Zhi 20, 95–97 (1999).
1.
Wu, V.-C., Lin, S.-L., Lin, S.-M. & Fang, C.-C. Treatment of baclofen overdose by haemodialysis: a pharmacokinetic study. Nephrol. Dial. Transplant. 20, 441–443 (2005).
1.
El-Husseini, A., Sabucedo, A., Lamarche, J., Courville, C. & Peguero, A. Baclofen Toxicity in Patients with Advanced Nephropathy: Proposal for New Labeling. American Journal of Nephrology 34, 491–495 (2011).
1.
Meillier, A. et al. Baclofen-Induced Encephalopathy in End Stage Renal Disease, Baclofen-Induced Encephalopathy in End Stage Renal Disease. Case Reports in Medicine, Case Reports in Medicine 2015, 2015, e203936 (2015).
1.
Mousavi, S. S. B., Mousavi, M. B. & Motemednia, F. Baclofen-induced encephalopathy in patient with end stage renal disease: Two case reports. Indian J Nephrol 22, 210–212 (2012).
1.
National Kidney Foundation. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update. Am. J. Kidney Dis. 66, 884–930 (2015).
1.
Bailie, G. R. et al. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int 87, 162–168 (2015).
1.
Bailie, G. R. et al. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int 87, 162–168 (2015).
1.
Weiss, G. & Kronenberg, F. Intravenous iron administration: new observations and time for the next steps. Kidney Int 87, 10–12 (2015).